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SUMMARY  
Despite more than a century of research, there is still no cure for amyotrophic lateral sclerosis (ALS) 
and the only available therapeutic extends survival by mere months. The most common motor neuron 
(MN) disease, ALS is traditionally characterised by selective degeneration of MNs and the 
systematic destruction of the motor system. However, in the last decade the classification of ALS is 
evolving from a pure MN disease to be considered instead a multi-system, non-cell autonomous and 
complex neurodegenerative disease. With new insights into the pathological mechanisms underlying 
ALS there is increased interest in the regulatory mechanisms that may compromise MN function, in 
particular those that may contribute to an excitatory and inhibitory imbalance in the disease. Indeed, 
there is great interest in determining the biological basis for increased cortical hyperexcitability and 
impaired inhibition identified in the motor cortex of both familial and sporadic ALS patients. It is 
proposed that altered motor network excitability may be a central pathogenic mechanism in the 
disease, possibly initiating the final progressive decline of motor neuron function. While intrinsic 
regulation of the MN is likely implicated in this pathophysiology, loss of inhibitory network function 
is presumably mediated by intra-cortical inhibitory interneurons; however, the exact cell types 
responsible are yet to be identified. As such, the intent of this thesis was to examine the role of key 
inhibitory neuronal populations in the cortex, as they are crucial for normal brain functioning and the 
balance of excitatory neurotransmission. The current thesis is based upon the hypothesis that the 
“ALS pathogenesis involves cortical interneuron dysfunction”.  
The current thesis examined the role of cortical interneurons in disease by first establishing a timeline 
of cortical interneuron involvement in the motor circuitry of the SOD1G93A mouse model of ALS. 
The intent of this initial study was to determine which interneurons are involved in disease, and the 
time frame of their alteration relative to symptom-onset and motor neuron deficits. Subsequently, the 
validity of interneuron pathology was established in post-mortem ALS cases. An additional aim of 
this secondary study was to determine the relationship between interneuron pathology, cortical 
pathology and clinical characteristics. The final study investigated the potential vulnerability of 
interneuron populations using an in vitro approach, with electrophysiological techniques designed to 
explore the innate susceptibility of interneurons in the presence of the SOD1G93A mutation.  
This thesis determined that specific interneuron populations were altered within the motor cortex of 
the SOD1G93A mouse model of ALS. Moreover, a novel timeline of interneuron involvement was 
identified that included dynamic changes in the density of NPY- and CR-expressing interneuron 
populations throughout the disease course. Changes originated in the upper cortical layers of the 
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motor cortex from early symptom onset, and progressed to involve the entire motor cortex by end-
stage. Interneurons were unaltered in the somatosensory cortex, nor other interneuron populations 
altered in either region, suggesting NPY and CR-interneurons represent a motor-specific inhibitory 
phenotype early in disease. Interestingly, pathology is found to change throughout disease, 
suggesting inhibitory involvement may not be a static phenomenon.  
The validity of interneuron involvement was subsequently investigated using post-mortem ALS 
cases. Comparing ALS cases and controls revealed changes in CR and NPY interneurons that largely 
recapitulated the interneuron pathology observed in the SOD1G93A mouse model. NPY-pathology was 
clearly increased in all ALS cases examined, supporting a similar pathogenic process in the motor 
cortex of ALS patients and the SOD1G93A mouse model. However, CR-interneuron pathology was 
recapitulated in a proportion of ALS cases, suggesting innate differences in the extent of interneuron 
involvement in individual cases. While no clear link was observed between interneuron pathology 
and clinical case characteristics, a positive correlation was demonstrated between heterogeneous CR-
interneuron pathology, NPY-pathology and pyramidal pathology, which may provide a novel 
perspective on the neuronal basis of circuit dysfunction in the ALS motor cortex. In support of a role 
for inhibitory dysfunction in ALS, the examination of cortical interneurons in vitro identified that 
populations were innately susceptible to the SOD1 mutation, as demonstrated by the alteration of 
intrinsic electrophysiological properties and morphological development.  
Collectively, these studies provide strong evidence in support of the hypothesis that the “ALS 
pathogenesis involves cortical interneuron dysfunction.” Herein, evidence is provided for a dynamic 
and continual influence of interneurons throughout disease, which may include subtype specific 
dysfunction, initiated during early development, influencing disease-associated circuitry until the 
final stages of disease. These results highlight the non-cell autonomous nature of ALS, and suggest 
that further efforts should be made to understand the biological basis of inhibitory deficits in the 
disease. This will be essential for future efforts aimed at the restoration of normal excitability for the 
treatment and prevention of ALS, as the efficacy of treatment regimes will likely depend on the 
extent, type and timing of underlying dysfunction, and therefore pathophysiology, in the disease. 
Equally, it may also be of great therapeutic benefit to investigate the potential compensatory 
processes initiated, or contributed to, by these diverse cortical interneuron populations. 
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1 INTRODUCTION 
First described by Jean-Martin Charcot in 1869 (Charcot & Joffroy 1869), amyotrophic lateral 
sclerosis is a progressive neurodegenerative disorder that has become synonymous with the 
systematic destruction of the motor system. Characterised by the loss of upper motor neurons 
within the brain and lower motor neurons within the spinal cord (Figure 1.1), it is the most 
common form of motor neuron disease (Cleveland & Rothstein 2001, Bruijn et al 2004, Talbot 
2014). An incurable and ultimately fatal disease, it has an annual incidence of 2/100,000 
individuals and a mean onset of 55-60 years (Chio et al 2013). The loss of motor neurons rapidly 
destroys the motor system and the ability to control voluntary muscles required for walking, 
talking, swallowing and breathing (Hardiman et al 2011).  
Clinically heterogeneous, ALS often begins focally with patients typically experiencing fatigue, 
cramp, muscle weakness and wasting of one or more limbs (defined as limb onset), or 
fasciculation of the tongue (bulbar onset) (Turner & Swash 2015). Approximately 35% of cases 
begin in a lower limb, 30% in an upper limb and 30% in the muscles involved in speech and 
swallowing, while a smaller percentage is initiated in the respiratory muscles (Figure 1.1) (Chio et 
al 2011, Swinnen & Robberecht 2014). In classical ALS this is followed by a diffuse and ordered 
spread of pathology throughout motor networks that culminates in progressive muscle weakness, 
atrophy and eventual paralysis, resulting in respiratory failure and death within 2 – 5 years of 
symptom onset (Ravits & La Spada 2009, Verstraete et al 2014). The systematic spread of 
pathology from a specific anatomical site raises a number of fundamental questions - what causes 
the initial onset of disease in a particular region? How does it spread? And what underlies the 
vulnerability of both the network and neurons implicated in the disease?  
At the system level the disease has been suggested to be propagated through defined anatomical 
networks by a cell-to-cell mediated ‘prion like’ mechanism involving the spread of pathogenic 
proteins (Lee & Kim 2015, Maniecka & Polymenidou 2015), or by degeneration passing though 
specific synaptic networks (Casas et al 2016). While either scenario is plausible, the complexity of 
such a biological basis is added to by the finding of subtle cognitive abnormalities in up to 50% of 
ALS patients, and pure frontotemporal dementia (FTD) symptoms such as behavioural, 
personality and language dysfunction in 15% of ALS patients (Ferrari et al 2011). Consequently, 
ALS is now considered a multi-system disorder in which patients can present with predominate 
motor symptoms, mixed motor and cognitive dysfunction, or cognitive predominance with minor 
motor involvement (Figure 1.2) (Ling et al 2013, Guerreiro et al 2015). Intriguingly, in either 
  
 
 
 
 
 
 
Figure 1.1. Site of onset in ALS. 
In the field there remains a number of points of contention that are of clear therapeutic 
and clinical consequence, including the site of disease origination and the primary 
process of spread. a, In particular, it is unclear whether the disease begins 
independently in lower motor neurons and upper motor neurons, or whether it is 
initiated primarily in the motor cortex, subsequently spreading to lower motor neurons 
(green arrow) in a process termed the “dying forward hypothesis.” The contrasting 
theory suggests ALS results from a dying-back change at the neuromuscular junction 
associated (blue arrow) with axonal degeneration retrogradely propagated throughout 
the motor system. b, This controversy is supported by the seemingly disparate onset of 
symptoms, where patients can present with a range of key symptoms including the 
most common limb onset, and the less frequent bulbar or respiratory onset. Patient 
phenotype is strongly influenced by the degree of lower motor neuron (orange) and 
upper motor neuron involvement (blue), but also by the severity of involvement in 
distinct anatomical regions (grey shading). However, the spread of pathology through 
adjacent anatomical regions, to encompass the entire motor system, suggests a common 
final neurodegenerative pathway in the disease.  
  
“The phenotypic variability of amyotrophic lateral sclerosis, Swinnen & Robberecht, 2014”
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presentation higher order cognitive functions such as memory, problem solving and spatial 
orientation are spared (Strong et al 2009). Likewise, not all motor neuron populations degenerate, 
as eye movement and bladder control are unaffected by disease progression (Bruijn et al 2004). 
Therefore, it is essential to understand the interaction between system level vulnerability and 
cellular degeneration in order to understand the pathogenesis of disease. 
At the cellular level a number of molecular and biochemical pathways have been implicated in the 
dysfunction of motor neurons and allow for insight into the potential pathogenicity underlying the 
disease. These include oxidative and proteasome stress (Karademir et al 2015), excitotoxicity 
caused by aberrant glutamate signalling (Van Den Bosch et al 2006), mitochondrial dysfunction 
(Carrì et al 2016), cytoskeletal dysfunction and axonal transport deficits (Clark et al 2016b), 
neuroinflammation (Hooten et al 2015), endoplasmic reticulum and protein folding stress (Matus 
et al 2013). While it remains to be determined which are primary disease mechanisms involved in 
the initiation of the disease, it is quite likely that mechanisms are not mutually exclusive, but 
instead are interconnected pathological processes, reflected by the non-cell autonomous nature of 
the disease (Figure 1.3)(Ilieva et al 2009). This is supported by the incredible spectrum of genetic 
factors now associated with the disease, which implicate a range of factors including RNA 
toxicity, maintenance of protein homeostasis and axonal transport (Renton et al 2014). 
Furthermore, while the majority of ALS cases are sporadic, with only ten percent of cases 
implicating genetic mutations (Al-Chalabi et al 2012), similarities in the clinical presentation of 
both the genetic and non-genetic forms of the disease have led to the suggestion of a commonality 
in the final neurodegenerative pathway (Byrne et al 2012). While several cellular, genetic and 
molecular mechanisms are likely involved in these common pathways, as a system-wide disorder, 
it is increasingly apparent that overactivation and abnormal excitability of circuitry may be of 
central importance in the disease (Eisen et al 1993, Vucic et al 2011, Bae et al 2013, De Carvalho 
et al 2014).  
Excitation and inhibition are critically balanced in the central nervous system, such that alterations 
in one should be counteracted by alterations in the other (Lehmann et al 2012, Kepecs & Fishell 
2014, Kubota 2014). In ALS, this homeostatic regulation appears to fail, with the manifestation of 
altered excitability evident in circuitry at critical stages in disease (Kuo et al 2004, Vucic & 
Kiernan 2006a, Vucic & Kiernan 2006b, Pambo-Pambo et al 2009, Bae et al 2013, Vucic et al 
2013, Menon et al 2014, Fogarty et al 2015). This typically presents as a ‘hyperexcitability’, 
whereby MNs generate a greater number of action potentials per unit of input (Neumann & 
Nachmansohn 1975). The outcome of this overstimulation was first proposed by Eisen in 1992 
  
 
 
 
 
 
 
 
 
Figure 1.2. ALS a multi-system disorder on a spectrum with FTD.  
Advances in gene wide association studies have led to considerable breakthroughs in 
our understanding of ALS. a, Most prominently the identification of the C9orf72 repeat 
expansion in both ALS and frontotemporal dementia (FTD)(a), which has placed these 
two seemingly distinct diseases on a continuum that may represent a broader category 
of neurodegenerative disease. b, Neuropathological studies have provided further 
credence to this notion, as TDP-43 is identified as the major protein constitute of 
inclusions in both ALS and FTD, reflecting pathological overlap in the diseases. The 
identification of clinical symptom overlap in patients, alongside potential monogenic and 
polygenic involvement of overlapping genes, suggests genetic penetrance may have a 
important role in the disease and highlights their may be a greater genetic component to 
the disease than previously appreciated.  
 
 
  
“Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis, 
Ling et. al. , 2013”
a
b
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(Eisen et al 1992), suggesting that hyperexcitability drives MN degeneration through a mechanism 
of glutamate-mediated excitotoxicity, driven by excessive calcium overload, leading to cell death.  
Although several molecular mechanisms may be implicated in this pathophysiology, this 
introductory thesis chapter will focus on the regulation of MN excitability. In particular, the 
extrinsic control of MNs is considered in relation to motor neuron hyperexcitability, highlighting 
inhibitory control of excitability and the potential contribution of altered inhibition to ALS disease 
processes and vulnerabilities.  
1.1 A GENETIC CONVERGENCE ON ALTERED EXCITABILITY  
In ALS the majority of cases are deemed sporadic (SALS) with no known cause, however, ten 
percent of cases are familiarly inherited (FALS) and have led to the identification of over 16 
different genes and genetic loci associated with the disease. The most common genes implicated 
include a hexanucleotide repeat expansion in the C9orf72 gene (39.3%) (DeJesus-Hernandez et al 
2011, Renton et al 2011), and mutation of the genes Superoxide Dismutase (SOD1) (12-23.5%) 
(Rosen et al 1993), TAR DNA Binding Protein (TARDBP) (5%) (Sreedharan et al 2008, Vance et 
al 2009) and Fused in Sarcoma (FUS) (4.1%) [reviewed in (Renton et al 2014)]. With the 
identification of the C9orf72 expansion also in 8% of SALS (Majounie et al 2012), there is 
increased interest in pathogenic mechanisms that may represent a point of genic convergence in 
the disease, such as altered excitability. 
Several clinical and experimental studies suggest a genetic convergence on altered motor neuron 
excitability in both sporadic ALS and familial forms of the disease with mutations in C9orf72, 
SOD1, TDP-43 and FUS (Delestree et al 2014, Wainger et al 2014, Devlin et al 2015). Altered 
excitability has predominantly been associated with spinal pathology in ALS, due to the suggested 
relationship of fasciculation with LMN populations (De Carvalho & Swash 1998, Kleine et al 
2008). However, more recently hyperexcitability has been shown to develop in both UMN (Eisen 
et al 1993, Vucic & Kiernan 2006b, Vucic et al 2013, Fogarty et al 2015) and LMN compartments 
(Kuo et al 2004, Kanai et al 2006, Vucic & Kiernan 2006a, Pambo-Pambo et al 2009).  
Indeed, a number of clinical studies support a central role for cortical hyperexcitability in ALS 
(Eisen et al 1993, Zanette et al 2002b, Vucic & Kiernan 2006b, Vucic et al 2008). Traditionally 
UMN excitability measures were clinically evasive (Swash 2012), however more recent 
transcranial magnetic stimulation (TMS) studies have allowed for the earliest changes in 
excitability to be studied (Vucic et al 2013). Intriguingly, cortical hyperexcitability has been 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.3. ALS as a non-cell autonomous disease 
While ALS has been traditionally viewed as a disease of pure motor neuron 
dysfunction, there are now several molecular and cellular mechanisms recognised to 
impede the function of other neuronal and non-neuronal populations in the disease. 
Considered as a non-cell autonomous disease, there is increasing interest in the 
supportive and regulatory cell populations required for normal motor neuron health and 
function. It is increasingly thought that the convergence of these supportive cell types 
may underlie major aspects of disease pathogenesis.  
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identified in sporadic and familial forms of disease and precedes both the onset of clinical 
symptoms and measurable LMN dysfunction (Vucic & Kiernan 2006b, Vucic et al 2008, Menon 
et al 2014). This indicates that imbalances in motor cortex excitation may be a pathological event 
occurring upstream of LMN dysfunction. In line with this, cortical hyperexcitability has been 
linked to the anterograde trans synaptic propagation of glutamate toxicity (Menon et al 2014), 
leading to LMN degeneration (Vucic et al 2013), an adaption of the dying forward theory of ALS 
pathogenesis first proposed by Eisen (Eisen et al 1992). While it still cannot be discounted that 
perhaps cortical hyperexcitability may occur independent (Ravits et al 2007, Ravits & La Spada 
2009) of, or secondary to (Pamphlett et al 1995), LMN dysfunction and degeneration, a relative 
loss of corticomotoneurons will have a greater clinical effect than loss of other MNs (Eisen & 
Weber 2001). Despite this controversy, as this chapter will emphasise, many studies in cellular 
and transgenic models of ALS highlight a primary role for altered excitability in both UMN and 
LMNs (Sareen et al 2013, Wainger et al 2014, Devlin et al 2015). 
1.1.1 Temporal dynamics of excitability – protective or pathogenic? 
Measures of excitability in transgenic animal models have suggested that a continuum of dynamic 
alteration is present throughout disease, which may represent, not only responsive compensatory 
mechanisms, but also initiating factors. Complimenting clinical studies, hyperexcitability is 
established in the G93A-hSOD1 mouse at embryonic (Pieri et al 2003, Kuo et al 2004, Martin et 
al 2013), neonatal (van Zundert et al 2008, Fogarty et al 2015, Saba et al 2015) and adult stages 
(Carunchio et al 2010) in both spinal and cortical cultures and acute cortical slices. However, 
transient states of both hyperexcitability, and hypoexcitability, are present throughout the disease 
course. In G93A-hSOD1 mice between postnatal day 34 and 82 at a presymptomatic stage, a third 
of spinal MNs have been reported to transition to hypoexcitability (Delestree et al 2014) and at 
end-stage hyperexcitability is absent (Fuchs et al 2013). The importance of varying excitability 
states is further confirmed by recent studies that demonstrate excitability is a disease-modifying 
factor capable of determining the fate of MNs. Disease-resistant MN populations are 
hyperexcitable, while vulnerable populations are unaltered (Leroy et al 2014). Additionally, 
generation of excitability in a vulnerable MN population has been shown to be capable of 
reversing disease pathology (Saxena et al 2013).  
While a wide range of evidence has implicated early intrinsic spinal MN hyperexcitability, and 
pre-symptomatic cortical hyperexcitability, more recent studies in pluripotent patient stem cell 
lines (iPSCs) suggest a genetic divergence in excitability. For example, neurons with the C9orf72 
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expansion demonstrate a decreased capacity for action potential initiation (Sareen et al 2013), 
while hyperexcitability is also reported in neurons with the SOD1, C9orf72 and FUS mutations 
(Wainger et al 2014). These studies highlight a common pathway of altered excitability 
alterations, however they also highlight an apparent contradiction of hypoexcitability and 
hyperexcitability in iPSC neurons with the C9orf72 expansion. This conflict is explained by a 
recent study that followed both TDP-43 mutation and C9orf72 expansion iPSCs over a 10-week 
period, finding an initial phase of hyperexcitability, which was followed by a progressive loss of 
both action potential output and synaptic activity (Devlin et al 2015). This suggests key disease-
related genes may be involved in a progressive alteration of excitability throughout the life of a 
neuron. Indeed, it is theorised that this transition from hyper to hypoexcitability may represent the 
pathogenic decline of the MN, whereby chronic over-excitation initiates more spikes in response 
to a synaptic input and subsequent intracellular calcium overload leads to neuronal death. This 
theory is further substantiated by in vivo recordings from G93A-hSOD1 mice that demonstrate a 
proportion of spinal MNs become hypoexcitable at a stage just prior to neuromuscular denervation 
(Delestree et al 2014). Thus, a progression from hyperexcitability to hypoexcitability may 
represent a common final pathway in vulnerable MN populations (Figure 1).  
Supporting this hypothesis in the context of ALS, aberrant electrical activity of MNs has been 
linked to dysfunction, degeneration and the accumulation of misfolded proteins (Kiskinis et al 
2014). In pluripotent stem cell-derived MNs activation of voltage-gated potassium channels 
reversed hyperexcitability and improved MN survival in vitro (Wainger et al 2014). Intriguingly, 
voltage-activated Na+ and K+ currents are reduced with advanced disease and the onset of 
hypoexcitability (Devlin et al 2015), indicating dysfunction or loss of ion channels may also have 
an important role to play in the disease, influencing the probability for normal neuronal activity 
and cell excitability. However, in contrast to this pathogenic view of hyperexcitability, in 
transgenic SOD1 mice increased excitability is demonstrated to protect vulnerable fast fatiguing 
spinal MNs normally lost in this model. The neuroprotective effect of enhanced excitability 
reversed misfolded SOD1 accumulation and MN pathology via activation of the mammalian target 
of rapamycin pathway (mTOR) (Saxena et al 2013). Importantly, further reduction of excitability 
in these populations enhanced misfolded SOD1 accumulation and accelerated disease. Hence the 
role of excitability in disease remains controversial, with both a pathogenic and neuroprotective 
role indicated. However, as a switch from hyperexcitability to hypoexcitability appears central to 
motor neuron decline, it may suggest that hyperexcitability is pivotal in a pathogenic switch, 
where resultant hypoexcitability ultimately defines the failure of motor neurons.  Taken together, 
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these findings indicate that maintaining balanced neuronal excitability throughout disease could be 
of therapeutic benefit. 
1.1.2 Glutamate-mediated excitotoxicity  
Excitotoxicity is caused by over-stimulation of neuronal glutamate receptors, leading to neuronal 
dysfunction and ultimately to cellular death through activation of Ca2+-dependent enzymatic 
pathways (Arundine & Tymianski 2003). A glutamate-mediated pathogenic process was first 
proposed in ALS due to elevated levels of glutamate observed in the cerebrospinal fluid (CSF) of 
patients (Rothstein et al 1990). A follow up study involving one of the largest investigations of 
patients with sporadic ALS, found increased CSF glutamate levels in nearly 40% of patients 
which correlated with disease severity (Spreux-Varoquaux et al 2002). Anti-glutamate drugs 
subsequently entered clinical trials, producing riluzole, the only drug currently approved for ALS 
treatment (Cheah et al 2010). With advances in clinical screening of patients, it is now apparent 
that enhanced glutamate release may also be a central pathophysiological process involved in 
hyperexcitability in both familial and sporadic forms of the disease (Vucic et al 2013).  
The release of glutamate during normal neurotransmission is a tightly regulated process (Figure 
1.4 a). Glutamate exerts its effects through both ligand-gated ionotropic receptors, including N-
methyl-D-asparate (NMDA), ∝-amino-3-hydroxyl-5-methyl-4-isoxazoleproprionic acid (AMPA) 
and kainate receptors, and G-protein-coupled (metabotropic) receptors, allowing calcium influx 
and action potential propagation (Seeburg 1993). The excitatory signal is terminated by active 
removal of glutamate via transporters (EAAT1 and EAAT2) predominately found on astrocytes 
surrounding the synapse (Vandenberg 1998). Astrocytes then convert glutamate to glutamine, 
which is recycled back to glutamate at presynaptic neurons via glutaminase and packaged into 
functional vesicles, ready to be released again (Danbolt 2001).  
In ALS evidence for a glutamate-mediated excitotoxic process has been provided in both human 
and animal studies (Figure 1.4 b). The glutamate transporters on astrocytes required for the rapid 
binding and clearance of synaptic glutamate (EAAT-2) have been reported to be dysfunctional in 
both the spinal cord and motor cortex of ALS patients (Lin et al 1998), and in the transgenic 
SOD1 mouse (Trotti et al 1999). Overexpression of EAAT-2 appears to be neuroprotective 
(Rothstein et al 2005), whereas downregulation accelerated disease progression (Pardo et al 2006). 
However, the loss of EAAT-2 does not appear to be a primary event in ALS, as abnormal 
glutamate transport is not unique to ALS and appears in several other neurodegenerative diseases, 
such as Alzheimer’s disease and Parkinson’s disease (Martin et al 1997, Hinoi et al 2005). Despite 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Glutamatergic neurotransmission (adapted from Heath & Shaw, 2002). 
a, Normal glutamatergic neurotransmission is highly regulated process in the central 
nervous system, which relies on regulatory mechanisms involving extrinsic synaptic 
influences and intrinsic cell properties. Inhibitory interneurons help regulate pre- and 
post-synaptic excitability and levels of glutamate released. Combinations of glutamate 
transporters effectively terminate glutamatergic effects on receptors by re-uptake and 
recycling of this excitatory neurotransmitter. b, When these regulatory mechanisms fail 
an excitotoxic calcium-mediated pathogenic process can damage neurons by the 
overactivation of receptors by increased extracellular glutamate. In ALS, excitotoxicity 
is thought to be a central pathogenic mechanism that may result from reduced 
astrocytic glutamate uptake, increased AMPA receptor permeability and increased 
excitability, potentially mediated by aberrant inhibition.  
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this, several studies have indicated that motor neurons are particularly vulnerable to excitotoxic 
insults (Bar-Peled et al 1999, Sun et al 2006, King et al 2007, Mitra et al 2013), with a most recent 
study supporting a die forward mechanism of excitotoxicity, chronic excitotoxin exposure of the 
lower motor neuron soma initiated neuromuscular denervation (Blizzard et al 2015). Motor 
neurons are known to have an innately low calcium-buffering capacity that may render them more 
susceptible to excitotoxic insults (Alexianu et al 1994). Adding to this, in the ALS disease setting 
patients have been found to have deficits in RNA-editing of the GluR2 glutamatergic AMPA 
receptor subunit (Kawahara et al 2004), which appears specific to motor neurons, rendering them 
highly permeable to calcium (Williams et al 1997).  
In combination such factors may explain innate vulnerability to normal glutamate levels, however 
calcium enters motor neurons not only through glutamate receptors during neurotransmission, but 
also through voltage-gated Ca2+ channels during each action potential (Powers & Binder 2001). 
Thus, the more excitable a cell is, the greater the calcium influx it may experience and the greater 
the likelihood of vulnerability to excitotoxicity. In the context of hyperexcitability, excessive 
glutamate release may therefore prime susceptible motor neurons towards excitotoxic 
degeneration. Hence there is great interest in the underlying factors that may be contributing to 
hyperexcitability in ALS.  
1.2 THE EXCITING PROSPECT OF INHIBITION IN ALS 
While intrinsic regulation of the MN is likely implicated in the pathophysiological basis of 
excitability changes in ALS (Williams et al 1997, Zanette et al 2002b, Zanette et al 2002a, 
Kawahara et al 2004, Kuo et al 2005, Kanai et al 2006), recent advances highlight the many facets 
of the inhibitory circuitry that are associated with extrinsic control of this selectively vulnerable 
population and may also contribute to disease (Andersen et al 1996, Weber et al 2000, Lorenzo et 
al 2006, Vucic et al 2008, Brockington et al 2013, Menon et al 2014). 
1.2.1 Inhibitory control of excitability  
In order to generate harmony in circuits, excitation must be balanced with an equally effective 
inhibition. In the central nervous system this balance is achieved through the regulatory actions of 
interneurons, a key inhibitory neuronal population that modulates the excitatory functions of 
pyramidal neuron populations throughout the brain and the spinal cord (Markram et al 2004). 
While the excitatory pyramidal neurons constitute the majority of neurons in the central nervous 
system, it is the incredible heterogeneity and diversity afforded by the remaining 20-30% of cells, 
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the interneurons, that allows for the fine-tuning of network excitability (Markram et al 2004). 
Typically classified by morphology, axonal targets, or by the expression of calcium binding 
proteins and neuropeptides (DeFelipe 2002, Markram et al 2004, Ascoli et al 2008, Suzuki & 
Bekkers 2010b), it is their differing intrinsic biophysical properties, connectivity and placement in 
networks that determines their functionality (Figure 1.5) (Buzsaki et al 2004, Wonders & 
Anderson 2006, Kubota 2014). In essence, as interneurons usually project locally they can 
modulate circuitry and affect output via either the presynaptic recruitment that drives the 
interneuron itself to fire, and/or by the post-synaptic targets of their inhibitory influence. These 
actions subsequently determine circuit activity and the output frequency of local pyramidal, or 
MN, populations (Kepecs & Fishell 2014). While interneurons receive both excitatory and 
inhibitory synapses themselves (Douglas et al 2004), it is the distinct axonal arborisation patterns 
exhibited by specific interneuron subsets that allow them to selectively control the input, 
integration and output of target cells (Buzsaki et al 2004). Interneurons can innervate the dendrite, 
soma or axon of neurons in different columns, or laminar, with great precision (DeFelipe 1997, 
Somogyi et al 1998). This elaborate diversity of connections can be thought of as divisive (axo-
axonic innervation) or subtractive (axo-somatodendritic) in nature and reflects the overarching 
complexity with which interneurons function to correctly apply balanced inhibition (Holt & Koch 
1997, Silver 2010).   
1.2.2 The motor cortex and its inhibitory cells 
Interneuron populations in the cortex have a role in the regulation of layer V corticomotoneurons, 
which are the major source of descending motor commands for voluntary muscle movement (Jara 
et al 2014). Fast spiking interneurons within the same cortical layer, directly synapse onto the 
corticomotoneurons and are thought to provide feedback or lateral inhibition (Tanaka et al 2011). 
Interestingly, interneurons located in layer II/III of the motor cortex, may also have a large impact 
on corticomotoneurons by disynaptic feedforward inhibition – a pathway from layer II/III to layer 
V is thought to represent the major excitatory input to corticomotoneurons (Thomson & Lamy 
2007), and the major synaptic output of the motor cortex (Yu et al 2008). Receiving descending 
inputs from the corticospinal tract system, spinal MNs (LMNs) focus motor activity, and also 
receive descending connections from other key motor structures, such as the basal ganglia and 
thalamus, many of them interneuronal (Miri et al 2013). The interneurons within the spinal cord, 
such as Renshaw cells, exhibit recurrent inhibition, in which they receive excitation from LMNs 
and in turn inhibit the same population of MNs (Renshaw 1941, Eccles et al 1954). They have 
actions upon α MNs initiating muscle contraction, γ MNs controlling muscle spindle length, 1a 
  
 
 
 
 
 
 
 
 
 
Figure 1.5 Cortical interneuron heterogeneity and classification 
a, Interneurons of the neocortex are localised to specific lamina in which they display 
substantial phenotypic diversity and can be classified by differences in cell morphology 
and molecular markers including but not restricted to: calbindin (CB), calretinin (CR), 
parvalbumin (PV), neuropeptide (NPY), somatostatin (SOM) and vasoactive intestinal 
peptide (VIP). Functional diversity can also be used to classify interneurons due to 
varying postsynaptic targets and projection patterns. b, The location of embryonic 
generation can also be used to classify interneurons, with differences in molecular 
markers, functional intrinsic properties and receptor profiles demonstrated in cells 
arising from caudal/lateral eminence (CGE) or medial ganglionic eminence (MGE).  
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interneurons mediating reciprocal inhibition of antagonistic muscles and other Renshaw cells 
(Alvarez & Fyffe 2007). Therefore, interneuronal control is important for many facets of motor 
system function, from the initiation of motor movements to the facilitation of firing in functional 
motor units.  
1.3 FUNCTIONAL CORRELATES OF INHIBITORY DYSFUNCTION IN ALS 
Over the last few decades a wealth of evidence has pointed towards an excitatory dysfunction in 
ALS motor circuitry (Caramia et al 1991, Eisen et al 1993, Prout & Eisen 1994, Mills & Nithi 
1998, Desiato et al 2002, Vucic & Kiernan 2006b, Vucic et al 2008), however it has remained 
unclear to what extent inhibitory alterations, or indeed interneuronal alteration, may underlie this 
pathophysiology. With the advent of transcranial magnetic stimulation (TMS) studies examining 
intracortical circuitry, it is has become evident that multiple measures of inhibitory regulation are 
pre-symptomatically disrupted.  
In ALS patients concurrent reductions in the short interval intracortical inhibition (SICI) 
(Hanajima et al 1996, Yokota et al 1996, Ziemann et al 1997, Sommer et al 1999, Zanette et al 
2002b), predominantly seen in patients with limb-onset disease, the cortical silent period (CSP) 
duration, predominantly seen in patients with bulbar-onset disease (Desiato et al 2002) and the 
resting membrane potential are documented (Menon et al 2014). Indeed, many of these TMS 
measures are now identified prior to LMN dysfunction and are associated with excitability in the 
cortex (Menon et al 2014). While some debate exists regarding the varying cortical components 
that are represented by these measures (Roshan et al 2003), it is a commonly held view that SICI 
is mediated by GABA-secreting inhibitory cortical interneurons via GABAA receptors (Ziemann 
et al 1996, Ziemann 2004). Although, perturbations that move neurons closer to their action 
potential threshold, such as alterations to voltage gated sodium (Na+) and potassium (K) channels 
may also contribute to reductions of SICI in ALS (Kuo et al 2005, Kanai et al 2006, Stafstrom 
2007). Nonetheless, CSP duration is thought to reflect both inhibition of anterior horn cells from 
the spinal cord and cortical influences via GABAB receptors (Cantello et al 1992, Inghilleri et al 
1993, Chen et al 1999, Werhahn et al 1999, Sanger et al 2001). Thus, the reduced CSP duration 
observed in ALS patients is likely in keeping with previous studies that have documented both 
disinhibition of anterior horn cells (Raynor & Shefner 1994, Drory et al 2001) and dysfunction of 
cortical inhibitory interneurons acting via GABAB receptors (Zanette et al 2002b).  
Further, evidence for interneuronal dysfunction is found in the motor cortex, where levels of the 
inhibitory neurotransmitter GABA is reduced (Foerster et al 2012), GABAA receptor subunit 
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alpha-1 mRNA is reduced (Petri et al 2003) and Flumazenil, a GABA receptor ligand shows 
reduced binding (Lloyd et al 2000). In this key-disease affected region concurrent losses of 
GABAergic activity is observed alongside elevated levels of glutamate (Foerster et al 2013). 
Therefore, a loss of cortical inhibitory influence (via GABAA and GABAB receptors dysfunction) 
and occurrence of ion conductance alterations (via Na+ and K channels) may concurrently 
facilitate increased motor network excitability. Together, these measures suggest a wider 
interneuronal phenotype that may underlie alterations in excitability and ultimately confer motor 
system vulnerability. 
1.4 PATHOLOGICAL EVIDENCE FOR INTERNEURON DYSFUNCTION 
In ALS a progressive destruction of motor control is emphasised by loss of UMNs (Betz cells) in 
the motor cortices (Udaka et al 1986), alpha and gamma MN losses in the spinal cord (Swash & 
Fox 1974, Swash et al 1986) and corticospinal degeneration (Swash et al 1988, Ellis et al 2001, 
Yin et al 2008). The functional deficit in ALS has therefore been assumed to result from 
motoneuronal death. However, a complex neuronal network controls the motor system, including 
interneurons that pervade these neuronal compartments (Jara et al 2014), and several histological 
studies support clinical findings and also suggest that inhibitory populations may be equally 
involved in pathology.  
1.4.1 The cortex 
In the ALS cortex a range of inhibitory populations have been implicated in pathology, however, 
evidence is fragmentary and there is a need for systematic investigations. In post-mortem ALS 
tissue, parvalbumin positive cells and neuropeptide Y positive neurites are decreased in the motor 
cortex (Nihei & Kowall 1993, Nihei et al 1993). Calbindin positive neurons have been reported to 
be unaltered in the motor cortex (Ince et al 1993), and to be reduced specifically in cortical layers 
V and VI (Maekawa et al 2004). A trend towards reduced calretinin positive cells is also 
demonstrated (Maekawa et al 2004). In the cortex of the G93A-hSOD1 transgenic mouse model of 
ALS, qualitative assessments suggest reduced calretinin cells in the motor cortex, but also in the 
hippocampus (Chung et al 2005). However, in contrast to findings in human cortical tissue, 
another study in G93A-hSOD1 mice found increased parvalbumin containing cortical interneurons 
in motor and somatosensory cortices (Minciacchi et al 2009). Thus, there appears a certain 
disconnect between human studies and animal studies, and while this may reflect clinical 
heterogeneity in patients or the divergent complexity of interneuronal circuitry between species 
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(DeFelipe 2002, DeFelipe 2011), it highlights the need for further histological studies aimed at 
determining interneuronal alterations.  
1.4.2 The spinal cord 
In the ALS spinal cord, a loss of anterior horn interneurons occurs in parallel, and to a similar 
extent, with MN losses in this region (Stephens et al 2006). Likewise, in the G86R-mSOD1 mouse 
model the temporal onset of degeneration in MNs and interneurons is reportedly the same 
(Morrison et al 1996, Morrison et al 1998). This suggests that the greater motor circuitry may be 
equally vulnerable in the ventral horn. In line with this theory, human spinal interneurons display 
similar pathology to degenerative MNs, with ubiquitinated cytoplasmic inclusions observed in 
some patients (Stephens et al 2001). However, also in the G93A-hSOD1 model, it has been 
reported that reduced glycinergic interneuron populations precede degeneration of MNs (Martin et 
al 2007, Chang & Martin 2009). Therefore, there may be differential vulnerability of glycinergic 
and GABAergic populations in this region.  
1.5 SELECTIVE MOTOR NEURON VULNERABILITY TO INHIBITORY DISTURBANCES 
Despite heterogeneity in the potential mechanisms of ALS (Bruijn et al 2004, Goodall & Morrison 
2006, Rothstein 2009), current studies lend support to differences in excitatory and inhibitory 
receptor profiles as key determinants of MN vulnerability and potential for survival.  
In ALS, not all MNs degenerate, rather there is spectrum of vulnerability in MN subtypes. 
Specific MNs are spared, such as the oculomotor and abducens populations responsible for 
preservation of eye movements in patients (Mannen et al 1977). Recent gene expression studies 
have explored the normal gene profiles of the subpopulations of MNs known to be either 
vulnerable or resilient to ALS (Brockington et al 2013). These studies have identified a number of 
factors that may contribute to differential vulnerability, including differences in genes implicated 
in ubiquitin-dependent proteolysis, mitochondrial function, immune system function and the 
extracellular matrix. However, the most striking differences were present in genes associated with 
functions in synaptic transmission, in particular genes responsible for the GABA and glutamate 
receptor subunits. In disease-resistant oculomotor neurons an upregulation of six different GABAA 
receptor units was identified compared to vulnerable spinal MNs (Brockington et al 2013). AMPA 
receptor subunits were also differentially altered with upregulation of GluR1 and GluR2 subunits. 
Indeed, the expression of GABAA receptor density ratios and synaptic and extrasynaptic GABAA 
receptors were altered in a separate gene study assessing differential features of ALS resistant 
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MNs (oculomotor, trochlear and abducens) compared with vulnerable MNs (facial, hypoglossal 
and trigeminal nerve) (Lorenzo et al 2006, Wijesekera & Leigh 2009). There are a number of 
reasons why these differing receptor profiles may produce differential vulnerability in the ALS 
disease setting, as discussed below.  
A baseline increase in GluR2 subunits in resilient MNs may maintain vital AMPA receptor 
calcium impermeability. The loss of the GluR2 subunit (Burnashev et al 1992, Lomeli et al 1994), 
causes AMPA receptors to become permeable to calcium (Van Damme et al 2002, Isaac et al 
2007), resulting in increased burden on downstream cell signaling cascades (Rothstein 2009). In 
ALS, defects in the RNA-editing of the GluR2 subunit are identified in sporadic patients 
(Kawahara et al 2004) and genetically engineered mice lacking ADAR, the enzyme responsible 
for normal GluR2 editing, develop symptoms suggestive of MN degeneration (Hideyama et al 
2010). Interestingly, ADAR2 has been identified as a site of TDP-43 misprocessing in sporadic 
ALS patient MNs (Yamashita & Kwak 2014), which may suggest a pathological convergence of 
the proposed RNA-editing dysfunction in ALS on this GluR2 subunit.   
GABAA receptors subunit composition determines the localisation of the receptor as well as its 
distinct pharmacological and electrophysiological properties thus differential GABAA subunit 
expression will alter GABAergic receptor function (Sieghart & Sperk 2002, Sigel & Steinmann 
2012, Labrakakis et al 2014). Furthermore an increase in GABAA receptors may allow for a 
greater extent of GABAergic influence and protection from altered neuronal activity such as 
excessive glutamate. This is supported by observations of reduced levels of the neurotransmitter 
GABA in ALS patients (Foerster et al 2012) and of the GABAA receptors alpha1-subunit in the 
motor cortex of patients (Petri et al 2003). Indeed, the hyperexcitability that develops in ALS 
(Eisen et al 1993) can be reversed by Diazepam, a prominent GABAA receptor agonist (Caramia 
et al 2000), indicating that loss of inhibitory input may be driving the hyperexcitability in this 
disease.  
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THESIS HYPOTHESIS AND AIMS 
Hyperexcitability and excitotoxicity are increasingly implicated in the pathogenesis of ALS, yet 
studies to investigate the pathological alterations to interneurons, a key regulator of excitability, 
are fragmentary. The great diversity of interneurons in the CNS has likely contributed to the 
failure to fully explore the role of this cell type in disease processes, with most studies focusing on 
pyramidal and motor neuron populations. There is accumulating evidence for a role of 
interneurons in ALS, however, this evidence is limited and a systematic investigation is required. 
This thesis aims to establish the role of cortical interneurons in ALS by firstly establishing a time 
course of interneuron pathology in the motor neuron circuitry of a well-established ALS mouse 
model. The validity of interneuron pathology is subsequently determined in human post-mortem 
ALS cases, examining neuronal pathology in key disease-associated cortical regions. Finally, the 
vulnerability of interneuronal populations is assessed in vitro in order to develop insight into the 
pathogenicity of interneurons in disease.  
Aim 1: Determine cortical interneuron involvement in the SOD1G93A mouse model of ALS. 
Hypothesis 1: The inhibitory motor neuronal circuit is central to disease in ALS, evidenced by 
specific interneuronal pathology in the motor cortex.  
Investigations focusing on interneuronal populations in the cortex are few and incomplete, despite 
increasing evidence of aberrant excitation in ALS. The first aim of this thesis will be to investigate 
if specific interneuron populations are altered in the cortex of the SOD1G93A mouse model of ALS. 
In addition, interneuron populations will be assessed at defined stages relative to disease 
progression, as less is known about the potential timing of inhibitory involvement in the disease. 
This will be completed by systematic assessment of specific interneuronal markers in cortical 
lamina utilising immunohistochemical and confocal microscopy techniques.  
Aim 2: Establish if specific interneuron pathology is recapitulated in human post-mortem 
ALS cortical tissue. Hypothesis 2: Specific interneuron populations affected in the SOD1G93A 
mouse are affected in ALS patients and are associated with the extent of cortical pathology.  
Inhibitory circuit dysfunction during early hyperexcitability is an increasingly recognised event in 
the ALS patient cortex. Further, GABAergic dysfunction and glutamatergic overload occur 
concurrently in the ALS motor cortex. Hence the inhibitory circuit is likely implicated in 
hyperexcitability and excitotoxicity in ALS. However, a cellular basis for inhibitory alterations in 
the ALS cortex remains to be determined. Therefore, Aim 2 will determine if interneuron 
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pathology identified in Aim 1 is present in post-mortem ALS cortical tissue. The extent of 
interneuron pathology will be established in individual cases and compared to cortical pathology 
after optimisation of relevant immunohistochemical markers.   
Aim 3: Identify the effect of the SOD1G93A mutation on interneuron development in vitro. 
Hypothesis 3: The SOD1 mutation will affect the intrinsic function of interneurons and their 
normal development in vitro.  
In ALS there is potential for early interneuron dysfunction to initiate, or respond to, changes in 
excitability. However, as interneurons are primarily considered an adaptive cell type, little is 
known about their innate vulnerability in disease. Despite studies that demonstrate motor neurons 
on an ALS genetic background have altered excitability and neurite development in vitro, it is 
unknown if interneurons are affected similarly. Therefore, using an in vitro primary culture model, 
Aim 3 will investigate the affect of the SOD1 mutation on normal interneuron function and neurite 
development, by examining intrinsic electrophysiological properties and neurite arborisation 
patterns.   
 
 
 
 
 
 
 
Chapter 2 
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2 A TIME COURSE OF DIFFERENTIAL INTERNEURON VULNERABILITY IN THE 
CORTEX OF THE SOD1G93A MOUSE MODEL OF ALS  
2.1 INTRODUCTION 
Clinical TMS studies have given incredible insight into the time frame and regional involvement 
of inhibitory/excitatory disturbance in the cortex (Eisen et al 1993, Zanette et al 2002b, Vucic & 
Kiernan 2006b, Vucic et al 2008, Menon et al 2014, Geevasinga et al 2015). In ALS, TMS 
critically identifies concurrent hyperexcitability and reduced inhibitory function in the motor 
cortex of both familial and sporadic ALS patients (Menon et al 2014, Geevasinga et al 2015). This 
is thought to contribute to an imbalance between inhibitory and excitatory synaptic drive to 
UMNs, which occurs prior to measurable lower motor neuron involvement and is linked to 
anterograde transynaptic propagation of glutamatergic toxicity. TMS studies suggest inhibitory 
dysfunction is mediated by intra-cortical inhibitory interneurons, however the parameters of TMS 
are such that it is difficult to identify the specific neuronal populations associated with 
pathophysiology (Menon et al 2014). This is particularly evident when investigating complex 
inhibitory cortical circuits, as a diverse range of interneurons comprise these networks, making it 
difficult to differentiate between individual populations (Ziemann 2004). Hence, there is relatively 
little known about the underlying architecture that may initiate inhibitory dysfunction in ALS, in 
particular the specific inhibitory populations involved and therefore interneuronal networks 
implicated in disease. Adding to this, it is difficult to establish a time course of alteration in ALS 
with either functional imaging studies or post-mortem histopathological studies, as patients are 
typically followed from symptom onset due to a lack of early biomarkers (Turner et al 2013, 
Benatar et al 2016). Moreover, investigation of other neurodegenerative diseases and cognitive 
disorders suggest that not all interneuron populations are equally vulnerable in disease with 
specific inhibitory populations susceptible in key disease-affected regions and neuronal layers 
(Kowall et al 1987, Baglietto-Vargas et al 2010, Lewis et al 2012). Therefore, despite increasing 
evidence that interneurons are likely of central importance in ALS pathophysiology, it is poorly 
understood which interneuron populations are involved in disease, and the time frame of their 
alteration relative to symptom-onset and motor neuron deficits.  
To address these gaps in our knowledge, this study aimed to determine the extent and timing of 
interneuron involvement in the cortex of the SOD1G93A mouse model of ALS (Gurney et al 1994). 
The transgenic SOD1 mouse has a substitution of glycine by alanine at residue 93 and is the most 
widely studied model of ALS (Kaur et al 2016). These mice are phenotypically normal at birth, 
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but begin to develop MN dysfunction at 8 weeks of age that progresses from hindlimbs to 
forelimbs presenting as weakness, tremors, reduced extension reflex, total paralysis and finally 
death (Azzouz et al 1997, Bendotti & Carri 2004, Wooley et al 2005).  
Traditionally this model has been used to investigate distal pathology, such as lower motor neuron 
dysfunction and loss (Gurney et al 1994, van Zundert et al 2008, Vinsant et al 2013, Delestree et al 
2014), it is only in recent years that the potential contribution of cortical pathology has begun to 
be investigated (Ozdinler et al 2011, Jara et al 2014). Recent studies show that corticospinal motor 
neurons mirror some of the earliest signs of degeneration that occur in lower motor neurons (Pieri 
et al 2009), including early electrophysiological changes, dendritic regression and cell loss (Pieri 
et al 2003, Kuo et al 2004, Kuo et al 2005). Additionally, dysfunctional astrocytes, microglia and 
oligodendrocytes have been shown to contribute to disease progression and motor neuron 
degeneration in SOD1 mice (Clement et al 2003, Beers et al 2006, Boillee et al 2006a, Wang et al 
2009, Lasiene & Yamanaka 2011, Nonneman et al 2014), increasing interest in the role of cortical 
neuronal and non-neuronal populations in these models (Boillee et al 2006a, Ilieva et al 2009).  
Importantly, alongside evidence of early cortical motor dysfunction (Ozdinler et al 2011), there 
are reports of increased excitability of layer V pyramidal cells in the motor cortex (Fogarty et al 
2015), which precede lower motor neuron symptoms (Vinsant et al 2013) and degeneration of 
cortico-spinal motor neuron pathways (Jara et al 2012). Furthermore, numerous studies have 
established hyperexcitability in this mouse model followed by hypoexcitability in a proportion of 
vulnerable motor neuron populations as the disease progresses (discussed in Chapter 1.1). 
However, the potential for an underlying interneuronal phenotype has not yet been fully explored 
in this ALS model. Therefore, the first aim of this thesis was to investigate a region-dependent 
vulnerability of specific interneuron populations in the cortex of the SOD1G93A mouse, and to 
investigate their fate at defined time points to establish a time course of disease-induced alteration. 
Immunohistochemical classification of interneurons is used to assess changes in numbers of key 
interneuron populations within the primary motor and secondary somatosensory cortices. Cell 
tracing software is used to assess changes in the morphology of key interneuron populations. The 
current investigation aims to determine the biological basis for inhibitory alteration in the 
SOD1G93A model to better understand the potential for therapeutic intervention aimed at the 
restoration of excitability in ALS.  
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2.2 METHODS 
2.2.1 Animals 
Male transgenic mice carrying a high copy number of the human SOD1G93A mutation on the 
human SOD1 promoter (Gurney et al 1994) [strain 004435 B6.Cg-Tg(SOD1G93A)1Gur.J - 
backcrossed for more than 10 generations on a C57BL/6 background] [Jackson Laboratory (USA) 
(http://www.jax.org/strain/004435)], and their wild-type littermates, were used for histological 
analyses. Animals were housed in individually ventilated cages at 20oC, on a 12 hour light-dark 
cycle, with access to food and water ad libitum. All procedures were approved by the Animal 
Ethics Committee of the University of Tasmania and conducted in accordance with the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes, 2013. 
2.2.2 Genotyping 
Mice were genotyped at the time of weaning (28 days post-natal) using a clipping from the end 
portion of the tail, which was removed and stored at -20°C until DNA extraction was undertaken. 
DNA was extracted using an Extract-N-Amp Tissue PCR tissue kit (Sigma-Aldrich) according to the 
manufacturer’s instructions and stored at -4°C. A multiplexed quantitative polymerase chain reaction 
was used to assess all mice for the presence of the SOD1G93A transgene and copy number determined 
according to standard protocols (25 ± 2) (Leitner et al 2009).  
Briefly, qPCR was performed as a 12.5µl reaction containing 50-100ng DNA (~1µl), 0.625µl ApoB 
F+R primer mix (500nmol, GeneWorks), 0.19µl SOD1 F+R primer mix (150nmol, GeneWorks), 1µl 
Tmol ApoB (0.15µmol, HEX TaqMan probe, GeneWorks), 1µl Tmol SOD1 (0.15µmol, 6-FAM 
TaqMan probe, GeneWorks), 6.25ul 2xSensiFAST SYBR no-ROX kit (Bioline, USA), 2.5µl milliQ 
water. The PCR amplification was carried out using the following primers: SOD1G93A transgene 
forward, 5’-GGG AAG CTG TTG TCC CAA G-3’; SOD1 transgene reverse, 5’-CAA GGG GAG 
GTA AAA GAG AGC-3’; ApoB forward, 5’-CAC GTG GGC TCC AGC AT-3’; ApoB reverse, 5’-
TCA CCA GTC ATT TCT GCC TTT G-3’ under the following conditions: 95oC for 5min, followed 
by 45 cycles of 95oC for 15sec, 45 cycles of 60oC for 15sec, 90sec preconditioning, 60-95oC, 5sec 
per step, on a Rotor-Gene Q (Qiagen, Germany). The apolipoprotein B (ApoB) gene was used as an 
internal positive control.  
2.2.3 Preparation of time-series cortical tissue from SOD1G93A and WT mice 
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SOD1G93A transgenic mice and age-matched wild-type controls were sacrificed from symptom 
onset in the SOD1G93A mouse (Ozdinler et al 2011) and assessed at defined time points until end-
stage in the disease course: 8 weeks (symptom-onset), 12 weeks, 16 weeks and 20 weeks of age 
(end-stage). The final time point was determined as an ethical stage preceding the 157-day typical 
life span in this SOD1G93A mouse model (Wooley et al 2005), and the earliest time point 
investigated when distal pathology has been previously described in our laboratory (Clark et al 
2016a). Mice were terminally anaesthetised (sodium pentobarbitone, 140mg/kg, i.p) and 
transcardially perfused with 4% paraformaldehyde (PFA; w/v) [(in 0.01M phosphate buffered 
saline (PBS)]. For each of the above time points, the cortex was obtained from six animals per 
genotype per time point. The brains were post-fixed in 4% PFA overnight at 4oC, then stored at 
4oC in 0.01M PBS containing 0.1% w/v sodium azide (Sigma Aldrich, Australia). 
Tissue processing. The brain was cut at Bregma -4.00mm, and the anterior portion cryoprotected 
with increasing concentrations sucrose (4%, 16%, 30%) dissolved in 0.01M PBS. Serial coronal 
cryostat sections (40µm) were generated using a Leica CM 1850 cryostat (Biosystems, Australia) 
and collected as free-floating sections into 24 well plates (Corning Life Sciences, USA) containing 
sodium azide, kept in sequential order and stored at 4oC until processed for 
immunohistochemistry.  
2.2.4 Immunolabeling for interneuron markers in SOD1G93A and WT cortex 
For analysis of cortical interneuron pathology, free-floating sections were processed using 
standard immunohistochemical methods (Blizzard et al 2016, Handley et al 2016). Cortical 
interneurons were identified by the expression of calcium binding proteins: calbindin (CB), 
calretinin (CR) and parvalbumin (PV), or by neuropeptides: neuropeptide Y (NPY), vasoactive 
intestinal peptide (VIP) and somatostatin (SOM)(Markram et al 2004). Every tenth serial sections 
(400µm apart) was incubated with antibodies recognizing cell-type specific interneuron markers 
diluted in 0.01M PBS containing 0.3% Triton-X-100 (see Table 2.1 for antibody dilutions). 
Following washes (3 x 0.01M PBS, 10min) to remove excess unbound antibodies, sections were 
incubated with alexa-fluor conjugated secondary antibodies (1:1000, Thermo-Fisher Scientific, 
Australia) diluted in 0.01M PBS at room temperature for 2hrs, followed by DAPI staining (4’,6-
diamidino-2-phenylindole, 1/50000, Thermo-Fisher Scientific, Australia). After further washes (3 
x 0.01M PBS, 10min), sections were mounted onto glass slides and coverslipped using fluorescent 
PermaFluor™ aqueous mounting medium (Thermo-Fisher Scientific Australia Pty Ltd, Australia). 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1.     Primary Antibodies used for immunohistochemistry in mouse cortex  
    
 
Antigen 
 
Description of Immunogen 
Source, Host Species, 
Cat#, Clone or Lot#, 
RRID 
Concentration 
Used 
    
Calbindin D-
28k 
Calcium-binding protein of the EF-
hand family related to calmodulin 
and troponin-C 
Millipore, rabbit 
polyclonal, 
Cat#AB1778 Lot#  
RRID:AB_2068336 
1:1000µl  
Calretinin Calcium-binding protein of the EF-
hand family related to calbindin D-
28k and calmodulin 
Swant, mouse 
monoclonal, 
Cat#6B3 
Lot#010399 
RRID:AB_1000330 
1:1000µl  
Parvalbumin Calcium-binding protein of the EF-
hand family related to calmodulin 
and troponin-C 
Swant, mouse 
monoclonal, Cat#235 
Lot#10-11 (F) 
RRID:AB_10000343 
1:1000µl  
Neuropeptide Y Neuropeptide Y conjugated to bovine 
thyroglobulin (BTg) with 
glutaraldehyde 
Immunostar, rabbit 
polycloncal, 
Cat#22940 
Lot#1112001 
RRID:AB_572253 
1:500µl  
 
Somatostatin Synthetic peptide coupled to keyhole 
limpet hemocyanin (KLH) with 
carbodiimide (CDI) linker 
Immunostar, rabbit 
polyclonal, 
Cat#20067 
Lot#216002 
RRID:AB_572264 
1:1000µl  
Vasoactive 
Intestinal 
Peptide 
Porcine VIP coupled to bovine 
thyroglobulin (BTg) with 
carbodiimide (CDI) linker 
Immunostar, rabbit 
polyclonal, 
Cat#20077 
Lot#1339001 
RRID:AB_572270 
1:1000µl  
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Specificity of all antibodies was verified by incubating sections with the corresponding secondary 
antibody without pre-incubation of primary antibody.  
2.2.5 Imaging and quantification 
Immunofluorescence was captured using a Zeiss LSM 510 DuoScan confocal microscope (Carl 
Zeiss Microscopy, Germany), running Zen software (V3.2, 2008) equipped with Ar488 and 
HeNe543 lasers. Cell bodies were quantified blind to genotype in the supragranular (layers I-IV) 
and infragranular lamina (layers V-VI) of the primary motor and secondary somatosensory 
cortices (Figure 2.1), comparable coronal sections were selected from 1.18mm to -0.58mm 
relative to bregma. Sections 21-36 according to the Paxinos and Franklin Mouse Brain Atlas 
(Paxinos & Franklin 2007). A plan-apochromat 20x objective (N.A. 0.8, Zeiss) was used to 
generate z-plane images with 2µm intervals through 16µm of tissue depth. Primary motor and 
secondary somatosensory cortices were identified by anatomical landmarks referring to the 
appearance of the lateral ventricles, the shape of the third ventricle and the appearance of the 
anterior commissure and corpus callosum, as visualized with DAPI staining and according to the 
Allen Mouse Brain Atlas (© Allen Institute for Brain Science: http://mouse.brain-map.org) 
(Figure 2.1). Immunopositive neurons (cells with positive labeling in cell soma) were counted 
using Image J software (National Institutes of Health, USA) with the integrated Cell Counter 
plugin utilising Nissl staining to identify cortical layers. To compare densities of immunopositive 
neurons in SOD1G93A and wild-type mice, all neurons within the regions of interest (ROI) were 
manually marked, counted and the density calculated using the area of the ROI (values are given 
in cells/mm2). The densities were then averaged across animals with 4 sections per cortical region 
per mouse included in analyses.  
2.2.6 Morphological analyses  
For analysis of neurite labelling patterns, 40µm coronal tissue sections were used to generate Z-
stack images of neurons with 1µm intervals through 16µm of tissue depth within the motor cortex. 
Neurons with full arbours within z-stack were analysed using the cell tracing software 
NeurolucidaTM (MBF Bioscience, USA) with the z-stack margins set to include one complete cell 
layer. For quantification of neurites immunoreactive for calretinin (CR), neurons were traced 
through stacks with processes marked, and images then exported to NeurolucidaTM Explorer II 
(MBF Bioscience, USA). Branched structure analysis was used to analyse the number, area and 
  
 
 
 
 
 
 
 
Figure 2.1. Representative images of sections used for quantitative analysis in WT 
and SOD1G93A mice. 
a, Coronal sections, each 40µm thick, from bregma 1.18 to -0.58 were used for 
quantitative analysis at four stages of disease progression in each cohort of mice. 
Arrows highlight anatomical landmarks used to identify primary motor (M1) and 
secondary somatosensory (S2) regions of interest in an example section used in the 
study (Interaural 4.06mm, Bregma 0.26mm), as identified in the Allen Mouse Brain 
Atlas and visualised by DAPI staining: namely the third (3V) and lateral ventricles 
(LV), shape and appearance of the corpus callosum (cc) and anterior commissure (aca). 
b, The motor cortex imaging site as validated in the Thy1-eYFP-H mouse, which has 
particularly prominent yellow fluorescent protein expression in large layer V 
corticospinal neurons (green) within the motor cortex57,80. c, A representative image of 
a calretinin (green), Nissl (red), DAPI (blue) cortical coronal section used for analyses. 
In each section, the motor (i) and somatosensory (ii) regions of interest (boxed areas 
enlarged to the right) were used for quantitative analyses, with cortical layers I-VI 
visualised by Nissl staining (iii).  
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length of primary, secondary, tertiary and quaternary order neurite processes, encompassing both 
axons and dendrites, of CR-labelled neurons.   
2.2.7 Statistical analyses 
Neuronal density was analysed using a two-way analysis of variance followed by Bonferroni post 
hoc tests (GraphPad Prism, Version 6.0) for group and regional comparisons. Overall group 
differences (main effects of genotype) were identified using non-parametric two-tailed t-tests. To 
assess neuronal densities across the disease course, three-way analysis of variance was used for 
comparisons of group and cortical regions between different time points (SPSS, Version 20). All 
variables were tested for statistical interaction, with any significant interactions included in the 
model. Statistical significance was set at P < 0.05. Average values were expressed as means ± 
standard error of mean. 
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2.3 RESULTS 
2.3.1 A subtype-specific interneuron alteration after symptom onset in the SOD1G93A motor 
cortex 
Within the cortex, inhibitory microcircuits are comprised of a wide variety of interneuron 
populations that target specific neuronal domains to facilitate the fine-tuning of cortical neuronal 
activity (Holt & Koch 1997, Silver 2010). These cell types are arranged in well-ordered wiring 
patterns that maintain the complex functions of cortical regions by their unique placement, 
connections and firing properties (Kubota 2014). Changes in specific interneuron populations are 
therefore likely to affect synaptic transmission in the motor cortex and compromise the regulation 
of network excitability, including motor output from layer V corticomotoneurons. To determine if 
specific interneuron populations were altered in the SOD1 cortex, we used immunohistochemistry 
to assess the potential for changes in the density of interneuron populations in the motor and 
somatosensory cortex of late-symptomatic (20 week) SOD1 mice, and in age and litter-matched 
wild type (WT) controls. Interneuron density was quantified (cells per mm2) in both the 
supragranular and infragranular lamina of motor (Ms, Mi) and somatosensory cortices (Ss, Si) to 
determine if cell position in cortical regions influenced pathology (Figure 2.1 a-c). GABAergic 
interneuron subtypes were differentiated according to the selective expression of calcium binding 
proteins [calbindin (CB), calretinin (CR), parvalbumin (PV)] and neuropeptides [neuropeptide Y 
(NPY), somatostatin (SOM), vasoactive intestinal peptide (VIP)](Markram et al 2004) (Figure 2.2 
a-f). Analysis revealed that of the interneuron populations expressing calcium-binding proteins, 
the density of CR-expressing neurons was significantly decreased in the supragranular lamina of 
the motor cortex (layers I-IV) (Figure 2.2 g-h). In this region, CR-neurons were reduced by up to 
37% of WT controls (55 ± 6 p/mm2 WT Ms, 35 ± 6 p/mm2 SOD1G93A Ms) (P < 0.05, two-way 
ANOVA, Bonferroni post-hoc) (Figure 2.2 j), while the density of this population remained 
unaltered in the infragranular motor cortex (32 ± 5 p/mm2 WT Mi, 19 ± 1.9 p/mm2 SOD1G93A Mi), 
and unaltered in both lamina of the somatosensory cortex relative to WT controls (43 ± 6 p/mm2 
WT Ss, 44 ± 4 p/mm2 SOD1G93A Ss; 12 ± 1 p/mm2 WT Si, 10 ± 1 p/mm2 SOD1G93A Si). No 
significant differences were detected in either of the other calcium binding populations, CB- or 
PV-expressing neurons in SOD1G93A mice and WT controls (Figure 2.2 i, k).  
In direct contrast, the density of NPY-expressing neurons was significantly increased by 29% in 
the supragranular motor cortex (41 ± 1 p/mm2 WT Ms, 54 ± 2 p/mm2 SOD1G93A Ms) and by 30% 
in the infragranular motor cortex of SOD1G93A mice compared with WT (35 ± 1 p/mm2 WT Mi, 46 
  
 
 
 
 
 
Figure 2.2. Calretinin and Neuropeptide Y interneuron subtypes are differentially 
altered in specific lamina of the SOD1G93A motor cortex.  
a-f, Calcium binding proteins and neuropeptides (green) were used to visualise specific 
interneuron populations in the cortex, showing labelling patterns of calbindin (CB; a), 
calretinin (CR; b), parvalbumin (PV; c) and neuropeptide Y (NPY; d), somatostatin 
(SOM; e) and vasoactive intestinal peptide (VIP; f) populations in 20 week WT cortex 
stained with DAPI (blue) and Nissl (red). The boxed areas (a-f) in the high 
magnification images show co-localisation of interneuron labels with Nissl stain. g-h, 
At 20 weeks, analysis of motor cortex, reveals the normal distribution of CR-
expressing interneurons in WT motor cortex (g), but a striking reduction in particular in 
layers I-IV of SOD1G93A motor cortex (h). Analysis of immunopositive neurons within 
the SOD1G93A motor (M) and somatosensory (S) cortex showed that the density of 
calretinin-expressing interneurons was significantly decreased specifically within the 
supragranular (Ms, layers I-IV) lamina of the motor cortex (j) and the density of 
Neuropeptide Y-expressing interneurons was significantly increased in both the 
supragranular (Ms, layers I-IV) and infragranular lamina (Mi, layers V-VI) of the 
motor cortex (l) (*P < 0.05, two-way ANOVA, Bonferonni’s multiple-comparison 
test). No other interneuron populations were significantly altered in either motor or 
somatosensory cortex (i, k, m, n). Values in graphs represent means ± SEM, n = 6 mice 
per group. Scale bar in (a-f) 20µm, (g-h) 100µm. 
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± 2 p/mm2 SOD1G93A Mi) (P < 0.05, two-way ANOVA, Bonferroni post-hoc) (Figure 2.2 l), an 
unexpected finding as interneurons in the cortex are generally not thought to undergo adult 
neurogenesis (Ernst & Frisen 2015). This suggests increased NPY density may more likely reflect 
increased expression of the NPY peptide on neurons. In the somatosensory cortex the density of 
NPY-neurons remained unchanged in both lamina (45 ± 2 p/mm2 WT Ss, 48 ± 3 p/mm2 SOD1G93A 
Ss; 29 ± 1 p/mm2 WT Si, 32 ± 1 p/mm2 SOD1G93A Si). Analysis of other neuropeptide expressing 
populations, SOM- and VIP-expressing neurons, identified no further differences in motor or 
somatosensory lamina compared to WT (Figure 2.2 m, n). These investigations demonstrate that 
at end-stage in the SOD1G93A cortex, at a time of established cortical vulnerability in this ALS 
model (Jara et al 2012), distinct regions of the motor cortex undergo selective alteration involving 
the differential vulnerability of neurons expressing CR and NPY.  
2.3.2 Contrasting and progressive alterations of NPY and CR populations throughout the 
SOD1G93A time course 
The early alteration of interneuron populations in the motor cortex could initiate a cascade of 
events resulting in an inability to maintain excitability in the cortex. In the TDP-43 model of ALS, 
SOM-expressing interneurons has been shown to initiate hyperexcitability in the motor cortex at 
an early disease stage (Zhang et al 2016). Therefore in this study the density of CR- and NPY-
expressing populations was examined at earlier stages in the SOD1G93A disease course: 8 weeks 
(from the earliest signs of symptoms in this model), 12 weeks and 16 weeks (Wooley et al 2005) 
(Figure 2.3 a). The mean density of CR-expressing neurons was decreased by 31% from (16 
weeks) in the supragranular motor cortex of SOD1G93A mice compared with WT (88 ± 13 p/mm2 
WT Ms, 60 ± 8 p/mm2 SOD1G93A Ms) (P < 0.05, two-way ANOVA, Bonferroni post-hoc) (Figure 
2.3 b). This decrease was not significant in the infragranular lamina of the motor cortex (61 ± 8 
p/mm2 WT Ms, 46 ± 6 p/mm2 SOD1G93A Ms), and was not present in the somatosensory cortex 
(71 ± 12 p/mm2 WT Ss, 48 ± 11 p/mm2 SOD1G93A Ss; 21 ± 9 p/mm2 WT Si, 17 ± 2 p/mm2 
SOD1G93A Si). The density of CR-expressing neurons remained unchanged relative to controls at 
earlier time points in the SOD1G93A cortex at 8 and 12 weeks. This suggests either a loss of CR-
expressing neurons, or a potential reduction in the expression levels of CR in this distinct 
interneuron population, occurs during the later symptomatic phase in this model and is restricted 
to the upper layers of the motor cortex.  
Interestingly, in contrast to the end-stage increase in the density of NPY-expressing cells in the 
SOD1G93A motor cortex (Fig. 2d), from symptom onset (8 weeks) the density of NPY-cells were 
  
 
 
 
 
 
 
 
 
Figure 2.3. Calretinin-expressing interneurons are progressively lost during the 
symptomatic phase in the SOD1G93A motor cortex. 
a, CR-expressing interneurons were labelled throughout the SOD1G93A disease course, 
showing neurons were present at comparable levels in SOD1G93A and WT mice at 8 
weeks (early symptom onset) and 12 weeks in motor (M) and somatosensory cortex 
(S). b, Analysis of 16 week symptomatic SOD1G93A mice showed that CR-expressing 
interneurons were significantly decreased in the supragranular lamina of motor cortex 
(Ms, layers I-IV) compared to WT mice. CR-expressing interneurons were 
progressively reduced in the supragranular lamina of motor cortex (Ms, layers I-IV) in 
20 week end-stage SOD1G93A mice (arrow heads in a) (*P < 0.05, two-way ANOVA, 
Bonferonni’s multiple-comparison test). Values in graphs represent means ± SEM, n = 
6 mice per group. Scale bar in (a) 50µm.  
  

  
 
 
 
 
 
 
 
Figure 2.4. Neuropeptide Y populations are differentially altered from early 
symptom onset in the SOD1G93A motor cortex.  
a, NPY-expressing interneurons were labelled at different stages in the SOD1G93A 
disease course: 8 weeks (early symptom onset), 12 weeks, 16 weeks and 20 weeks 
(end-stage). b, The mean density of NPY-expressing interneurons was significantly 
decreased in the supragranular lamina of the motor cortex (Ms, layers I-IV) in early 
symptomatic (8 week) SOD1G93A mice compared to WT (arrow heads in a). NPY-
expressing interneurons were present at comparable levels in SOD1G93A and WT mice 
at 12 weeks and 16 weeks, with a late increase in cell density detected throughout the 
motor cortex at 20 weeks in end-stage SOD1G93A mice (arrow heads in a). The 
somatosensory cortex showed no change in NPY-expressing interneurons at any stage 
of disease in supragranular (Ss, layers I-IV) or infragranular lamina (Si, layers V-VI) in 
SOD1G93A and WT mice (*P < 0.05, two-way ANOVA, Bonferonni’s multiple-
comparison test). Values in graphs represent means ± SEM, n = 6 mice per group. 
Scale bar in (a) 100µm.  
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significantly decreased by 17%, but only in the supragranular lamina of the SOD1G93A motor 
cortex (55 ± 1 p/mm2 WT Ms, 45 ± 2 p/mm2 SOD1G93A Ms) (P < 0.05, two-way ANOVA, 
Bonferroni post-hoc) (Fig. 2.4 a-b). The density of NPY-neurons remained unaltered in the 
infragranular lamina of the motor cortex (39.5 ± 3 p/mm2 WT Ms, 38 ± 2 p/mm2 SOD1G93A Ms), 
and in other somatosensory regions relative to WT controls assessed at this 8 week time point (49 
± 2 p/mm2 WT Ss, 53 ± 2 p/mm2 SOD1G93A Ss; 33 ± 2 p/mm2 WT Si, 31 ± 2 p/mm2 SOD1G93A Si). 
Notably, the density of NPY-expressing neurons from SOD1G93A mice were also unaltered in 
motor and somatosensory cortical regions investigated at 12 and 16 weeks relative to WT mice. 
These data suggest that changes to interneurons can occur early in the SOD1G93A motor cortex, is 
progressive with CR-expressing neurons, and may alter over the disease course in relation to 
NPY-expressing neurons. This may indicate that the alteration of different classes of interneurons 
varies across the disease course and that interneuronal alterations are not a static phenomenon in 
the SOD1G93A cortex. As an aside, it was also interesting to note that overall there were fewer cells 
counted in both the WT and SOD1G93A mice with increasing age, most notable at the 20 week time 
point. However, this is consistent with developmentally programmed cell death of cortical 
interneurons that occurs with synaptic pruning in the neocortex of mice. By 18 weeks of age 
approximately 40% of neocortical interneurons undergo programmed cell death in the mouse 
neocortex (Southwell et al 2012), similar to the generalised decrease in density observed in the 
WT mice in this study.  
2.3.3 Progressive CR-interneuron involvement in the supragranular SOD1G93A motor cortex  
A characteristic hallmark of neuronal degeneration is the alteration of neurite structure, which can 
precede overt changes in cell density, while augmenting connectivity patterns and the innervation 
field of neuronal populations (Kaas et al 1990, Darian-Smith & Gilbert 1994, Beirowski et al 
2004, Lee et al 2008, Blizzard et al 2011). Due to the progressive nature of CR-neuronal 
alterations, CR-expressing interneurons were investigated to determine if they were abnormal in 
SOD1G93A mice by examining branching patterns in 40µm coronal sections at two contrasting 
disease stages: an early symptomatic time point (8 weeks), prior to loss of CR-expressing neurons 
demonstrated at 16 weeks, and an end-stage time point, when CR-expressing interneuron loss had 
been established for a prolonged period in the SOD1G93A disease course. Immunolabeling of the 
supragranular lamina of the motor cortex revealed extensive differences between CR-labelled 
neurites from end-stage (20 week) SOD1G93A mice and WT controls. CR-neurons in WT tissue 
had well-developed and extensive neurite trees, whereas the same neurons in SOD1G93A tissue 
exhibited a substantial reduction in neurite labelling (Figure 2.5 b). Quantification confirmed this 
  
 
 
 
 
 
Figure 2.5. Calretinin-expressing neurites undergo progressive alterations in 
branching complexity from symptom onset in the supragranular SOD1G93A motor 
cortex.  
a-d, CR-labelled tissue sections were imaged and immunopositive neurons in the 
supragranular lamina assessed using cell tracing software to analyse neurite 
morphology (arrowheads, insets) at 8 weeks (a) and 20 weeks (b) in WT and SOD1G93A 
tissue. The division of the neurite structure into primary, secondary, tertiary and 
quaternary order processes (as observed with CR-labelling) was used for all 
investigations. c-d, A proportional analysis was conducted to determine the extent of 
CR-labelled processes remaining on neurons in the supragranular motor cortex at both 
time points, showing a significant increase in neurons with no, or fewer, CR-labelled 
processes visible in early symptomatic (8 week) SOD1G93A mice and in 20 week end-
stage SOD1G93A mice compared to WT. e-h, The mean branch length (e-f) and mean 
volume (g-h) of CR-labelled neurites were also assessed, demonstrating a pre-
symptomatic increase in the length and volume of distal neurite processes in 8 week 
SOD1G93A mice (e, g). Analysis of 20 week end-stage SOD1G93A mice showed a 
significant reduction in the length and volume of CR-labelled processes compared to 
WT (f, h) (*P < 0.05, two-way ANOVA, Bonferonni’s multiple-comparison test). 
Values in graphs represent means ± SEM, n = 6 mice per group. Scale bar in (b) 20µm.  
  

   38  
 
observation, revealing a significant reduction in the proportion of CR-positive neurons with 
primary (~70%), secondary (~25%) and tertiary (~14%) order processes in the SOD1G93A cortex 
compared with WT (Fig. 5d). This was accompanied by a nine-fold increase in the proportion of 
SOD1G93A CR-neurons with no neurites visible (Figure 2.5 d). Likewise, the average length of 
tertiary order processes (~48%) (Figure 2.5 f) and the average area of primary (~75%), secondary 
(~79%) and tertiary (~75%) order processes (Figure 2.5 h) was significantly decreased in the 
SOD1G93A motor cortex compared to WT. Overall group comparisons revealed that the SOD1G93A 
genotype significantly reduced the average length (~38%) and volume (~78%) of all CR-labelled 
neurites, independent of branch order (Figure 2.5 f, h). These results demonstrate that at end-stage 
the remaining population of CR-expressing neurons have an irregular distribution of CR-
immunoreactivity in their processes, which may translate into abnormal function in the motor 
cortex. 
Next the CR-labelling patterns in early symptomatic tissue (at 8 weeks) were investigated to 
establish if alterations were present prior to loss of CR-expressing neurons. Cell tracing revealed a 
similar, although more subtle, pattern of alterations to SOD1G93A CR-neurons at this time point 
(Figure 2.5 a). There was a significant reduction in the proportion of CR-expressing interneurons 
with primary neurites (~5%) and a small increase in cells with no processes visible (Figure 2.5 c). 
However, there was a trend towards a two-fold increase in the average length and area of neurites 
of CR-neurons in SOD1G93A tissue, which was only significant in quaternary order processes 
(Figure 2.5 e, g). These results strongly suggest a potential involvement of CR-networks in 
relation to motor neuron circuitry defects previously observed in the motor cortex. 
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2.4 DISCUSSION 
This current study sought to determine if there was cellular evidence indicating a loss of cortical 
inhibitory influence in the transgenic familial SOD1G93A mouse model. It was hypothesised that 
specific interneuron populations would be altered in the motor cortex, with investigations 
performed to assess changes in cell density, distribution and morphology throughout cortical 
lamina at defined stages relative to disease progression. The interneuron pathology reported here 
strongly support a sequence of inhibitory alteration, which is restricted to the motor cortex, 
includes specific interneuron populations, and begins early in disease at a stage when, according to 
previous reports, corticospinal motor neurons are altered in the SOD1G93A model (Jara et al 2012). 
Changes in CR- and NPY-expressing interneuron populations are evident from 8 weeks in the 
supragranular lamina of the motor cortex, progress to loss of CR-expressing neurons by 16 weeks, 
and include contrasting alterations of CR and NPY populations by end-stage disease at 20 weeks. 
The early involvement of both populations within the supragranular motor cortex indicates 
inhibitory cell deficits originate in the upper cortical layers (I-IV) of the motor cortex in the 
SOD1G93A mouse model. A significant increase in the length of the most distal (terminal) CR-
processes is also identified from 8 weeks, a number of weeks prior to their apparent loss at 16 
weeks, and prior to a marked decrease in their process complexity by end-stage. While it remains 
unclear why interneurons are vulnerable to disease, it is likely that their involvement is related to 
motor-specific structural and functional alteration. The current discussion highlights the potential 
for CR and NPY interneuron populations to underlie dysfunction in the motor cortex, emphasising 
how contrasting changes may represent a convergence on excitability. The structural changes in 
the motor cortex are also discussed in relation to the current findings. 
2.4.1 CR-interneurons and vulnerability to enhanced excitation  
Cortical interneurons are essential for the regulation of normal excitability, but it is increasingly 
apparent that CR-interneurons in particular are susceptible to pathogenic changes in excitability. 
In this study CR-expressing interneurons had reduced density and showed morphological 
abnormalities in the SOD1G93A mouse model. While it cannot be concluded if this represents loss 
of the protein or loss of the cell, there were changes consistent with altered network activity. In 
mouse models of epilepsy and in the epileptic human hippocampus increased excitability is 
accompanied by the loss of CR-containing interneurons and reorganisation of their neurites (Toth 
& Magloczky 2014). This is exemplified in the sclerotic hippocampus where the density of CR-
immunopositive neurons is significantly decreased, while in non-sclerotic hippocampus CR-
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interneurons are preserved (Toth et al 2010). When considered in the context of ALS, this may 
suggest a feedback mechanism whereby the loss of CR-interneurons translates to a loss of key 
excitatory neuronal populations, or vice verse. Additionally, it may suggest that reduced CR-
populations are involved in a loss of circuitry control, resulting in the hyperexcitability observed 
in ALS, and epilepsy. As interneurons play such a critical role in the modulation of cortical 
circuitry (as discussed in section 1.2), a loss of interneuron populations can contribute to 
overstimulation of glutamate receptors via excessive release of glutamate, resulting in Ca2+ 
mediated neuronal injury and death (Zeman et al 1994). Hence, the finding of altered morphology 
as early as 8 weeks in this study raises the possibility that CR-interneurons may be involved in the 
initial alteration of the motor network. It remains to be determined if this is a developmental 
phenomenon or due to disease progression at this early symptomatic stage in the SOD1G93A mouse 
model.  
2.4.2 The UMN circuit and CR-inhibitory networks in the SOD1G93A mouse 
While the mechanism responsible for the observed interneuron deficits require further 
investigation, the timing of changes in the cortex correspond well with early changes in the 
corticospinal motor neurons in the SOD1G93A motor cortex. Results from this study indicate CR-
interneuron networks are altered in the supragranular lamina of the motor cortex at 8 weeks. 
Within this region the majority of CR-interneurons reside within layer II/III, where they may 
directly synapse with apical processes from layer V corticospinal motor neurons and provide 
feedback or lateral inhibition (Cauli et al 2014). In SOD1G93A mice, it has been shown that at 8 
weeks the apical dendrites of layer V motor neurons located within layer II/III are severely 
degenerated and have reduced spine density, while the basal motor neuron dendrites in layer V do 
not exhibit overt signs of degeneration (Jara et al 2012). This may suggest unique regional 
involvement of CR-neurons is initiated by, or responding to, alterations in spine density of the 
apical corticospinal motor neuron dendrites within layer II/III of the motor cortex. Therefore, the 
dendritic inhibition of pyramidal neurons may be less effective. In support of this, the apical 
dendritic spines of layer V projection neurons, typically receive excitatory inputs from 
thalamocortical neurons and from local layer II/III neurons (Brecht et al 2013), whereas basal 
spines preferentially receive inputs from distal sensory and motor nuclei (Hooks et al 2013). 
Recent works suggest corticospinal motor neuron spine loss can occur at 3 weeks in the SOD1G93A 
mouse model accompanied by increased functional excitatory synaptic activity onto layer V 
pyramidal neurons (Fogarty et al 2015). Hence mutant SOD1 may mediate increased excitability 
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through early changes to spine dynamics, leading to apical dendritic regression and inhibitory 
neuronal alteration; however, aberrant inhibition may also have the capacity to initiate pathology.  
2.4.3 An initial vulnerability of CR-inhibitory networks in the SOD1G93A mouse 
It is increasingly recognised that the development of CR-interneurons is an activity dependent 
process and alterations in excitability can affect their morphology. In particular, the length of 
axonal arbours on both multipolar and bipolar populations is directly influenced by aberrant 
excitability during development (De Marco Garcia et al 2011). This raises the possibility that 
abnormal excitability may initiate abnormal maturation of the CR-interneuron innervation field. 
Furthermore, CR-interneurons are a unique inhibitory population in the cortical circuit, as they 
preferentially regulate the activity of other GABAergic inhibitory populations, and subsequently 
the actions of principal neurons via disinhibition (Gulyas et al 1996, Barinka & Druga 2010). In 
this manner, not only may CR-interneurons be more susceptible to early alterations in excitability, 
but they also have the ability to potentiate a wide reaching inhibitory and excitatory circuit 
dysfunction, due to their distinctive connectivity patterns and continual alteration throughout 
disease. The major excitatory input to corticospinal motor neurons is a pathway from layer II/III to 
layer V (Thomson & Lamy 2007); hence interneurons located within layer II/III may 
disproportionately influence corticospinal motor neuron activity via disynaptic feedforward 
inhibition (Cauli et al 2014). Indeed, the contrasting and somewhat unexpected involvement of 
NPY-interneurons may also support a continuum of pathogenic alterations triggered by altered 
excitability.  
2.4.4 The contrasting alteration of NPY  
As a loss of inhibitory influence is theorised in ALS, the finding of increased NPY-interneuron 
density at end-stage was an unexpected finding. A potential cause of this may be due to the effect 
of the SOD1G93A mutation on cortical thickness, driving alterations at different rates across the 
time course. However, this is not expected to be the case as other interneuron populations are not 
similarly affected. Another more plausible scenario for this observation may include the role of 
NPY as an endogenous neuroprotective compound in the context of increased excitability. 
Neuropeptides are preferentially released during sustained neuronal stimulation (Drexel et al 
2012), and are thought to protect neurons against increased pathogenic cortical activity (Tallent & 
Siggins 1999, Vezzani & Hoyer 1999, Tallent & Qiu 2008, Kovac & Walker 2013). Extensive 
literature from the epilepsy field supports a neuroprotective role for NPY as an endogenous anti-
epileptic (Kovac & Walker 2013). Mice lacking NPY are more susceptible to spontaneous and 
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pharmacologically induced seizures, which can be reversed by intracerebral administration of 
NPY (Erickson et al 1996, Baraban et al 1997). As it is generally thought that interneurons in the 
adult cortex do not undergo neurogenesis (Ernst & Frisen 2015), this indicates that the increased 
NPY density observed in this study more likely reflects up-regulation and increased expression of 
the peptide on existing neurons in the cortex that may not typically express this peptide under 
normal physiological circumstances. Indeed, increased synthesis and release of NPY has been 
reported following seizure activity (Vezzani & Sperk 2004, Kharlamov et al 2007) and increased 
the density of interneurons expressing NPY are described following excitotoxin treatment 
(Bouilleret et al 2000). This indicates increased NPY expression by interneuron populations may 
be an advantageous intrinsic mechanism to counteract increased activity of cortical excitatory 
neurons, potentially up-regulating NPY expression on a greater proportion of neuron populations. 
Therefore, our finding of increased density of NPY-immunoreactive neurons at end-stage may be 
a direct consequence of increased activity in the motor cortex.  
In line with this, it is quite interesting that the increased density of NPY populations was first 
restricted to the upper cortical layers of the motor cortex, where CR-populations are 
predominately altered, but by end-stage these NPY alterations were widespread throughout the 
entire motor cortex. This may suggest initial inhibitory deficits cause a localised change in 
excitability within the motor cortex, which spreads, resulting in increased NPY-immunoreactivity 
throughout the major excitatory pathways within the diseased motor cortex. In the context of our 
early results, this may suggest a late stage compensatory mechanism whereby NPY expression is 
upregulated to dampen the effects of altered excitability in motor circuitry. However, as this study 
demonstrates decreased density of NPY-interneurons at 8 weeks, excitability in the motor cortex 
may fluctuate throughout the disease course. In this respect, it is also interesting to note that both 
SOD1 and TDP-43 ALS models demonstrate the increasing involvement of neuropeptide systems, 
as somatostatin-interneuron density is reported to increase by late stages in TDP-43 mice (Zhang 
et al 2016). This is particularly important because it shows that not all interneuron populations 
may be involved in a similar manner in the disease, and the targeting of inhibitory populations for 
the restoration of normal excitability in the ALS cortex might best be considered in a 
subpopulation specific paradigm. It will be interesting and important to identify whether other 
genetic variants of the disease have a similarly distinct yet divergent interneuronal phenotype.  
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2.4.5 Conclusion  
While the role of the cortex in motor neuron circuitry is only just beginning to be elucidated, it is 
apparent that in the SOD1G93A mouse specific inhibitory populations may have an 
underappreciated role in the disease. This study clearly demonstrates a novel timeline of 
interneuron involvement in the SOD1G93A motor cortex. This included the specific change of 
NPY- and CR-expressing interneuron populations. Changes originate in the upper cortical layers 
of the motor cortex from early symptom onset, and progress to involve the entire motor cortex by 
end-stage disease. It is important to note this study primarily uses immunohistochemistry to 
investigate interneuron populations; hence it remains to be determined how interneuron alterations 
functionally influence the disease, whether pathology is primary or secondary to excitability, due 
to a developmental phenomenon or disease progression and protective or pathogenic in the context 
of the disease. Nonetheless, these findings suggest that inhibitory involvement may not be a static 
phenomenon, but instead involves dynamic changes throughout disease.  
 
 
 
 
 
 
 
Chapter 3 
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3 DIFFERENTIAL INTERNEURON PATHOLOGY IS A FEATURE OF THE HUMAN ALS 
MOTOR CORTEX 
3.1 INTRODUCTION 
It is important for pre-clinical insights gained from mouse models to be cross-validated in human 
disease, particularly as the major weakness of using animal models for ALS has been a failure to 
predict responses in humans and the subsequent failure to translate potential drug candidates into 
effective therapeutics (DiBernardo & Cudkowicz 2006, Ittner et al 2015, Justice & Dhillon 2016). 
Although fragmentary evidence of cortical interneuron involvement has been provided by previous 
human immunohistochemical studies (Ince et al 1993, Nihei et al 1993, Maekawa et al 2004), the 
current pilot study aimed to investigate interneurons in the ALS motor cortex to primarily establish 
the validity of findings from the SOD1G93A mouse model. It was hypothesised that specific 
interneuron populations affected in the SOD1G93A mouse would also be affected in ALS patients and 
associate with the extent of cortical pathology. This was reasoned as post-mortem neuropathology 
studies have shown reduced expression of GABAA receptor expression in the motor cortex of 
patients (Petri et al 2003) and both magnetic resonance spectroscopy imaging (MRSI) and positron 
emission tomography (PET) studies provide additional evidence for an early and diffuse loss of 
inhibitory cortical interneurons in the motor cortex. Moreover, the main inhibitory neurotransmitter, 
GABA, is reduced in the motor cortex of ALS patients (Foerster et al 2012) and PET scans reveal 
reduced binding of the GABA receptor ligand, flumazenil, in the motor cortex of sporadic ALS 
patients (Lloyd et al 2000), consistent with a loss of inhibitory interneurons. Longitudinal functional 
neuroimaging studies also suggest there is an initial phase of reduced intracortical inhibition, before 
loss of upper motor neurons (Mohammadi et al 2011), indicating inhibitory dysfunction may have an 
important role in motor neuron decline.  
However, clinical and pathological heterogeneity may also be an important factor in the failure of 
drug studies to date and there is an emerging research priority to establish methods capable of 
stratifying patients clinically (Turner et al 2009, Marin et al 2016, Zach et al 2016). This is 
exemplified by recent attempts to map the onset and spread of disease pathology throughout different 
brain regions (Brettschneider et al 2013, Fatima et al 2015), and to differentiate ALS from FTD 
variants using neuropathological grading (Tan et al 2015), with both strategies based on the 
prevalence of TDP-43 pathology. Notably, the study by Bretteschneider and colleagues indicated that 
while pathology extends to prefrontal, temporal and hippocampal regions with disease progression, 
lesions may first develop in the motor cortex, brainstem motor nuclei and spinal cord α-motor 
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neurons. Hence, considerable efforts remain focused on determining the pathological basis of 
vulnerability in motor regions, particularly as elucidation of disease mechanisms that occur early in 
disease would be more beneficial for targeting therapeutics. Interestingly, clinical studies indicate 
that intracortical inhibitory involvement may act as an early determinant of disease progression in 
ALS cases (Menon et al 2014). 
It is widely acknowledged that there is considerable clinical variation in the rate of disease 
progression in ALS, particularly as approximately 10% of all cases survive beyond 10 years of 
symptom onset (Chio et al 2011, Talbot 2014). Hence, it is notable that familial SOD1 mutation 
carriers with preserved intracortical inhibitory circuitry have a slower disease progression (Weber et 
al 2000), surviving an average of 13 years compared to three in sporadic patients (Andersen et al 
1996, Turner et al 2005). Conversely, but complimentary, in vivo clinical imaging studies have 
shown that sporadic ALS patients with greater intracortical inhibitory dysfunction have a more rapid 
clinical decline and shorter disease duration (Shibuya et al 2016). These studies not only support a 
role for interneurons in pathogenesis, but also indicate that preservation of inhibitory circuit function 
may be a viable therapeutic option to slow the rate of disease progression in patients. Hence, there is 
a need to better understand the cellular basis of inhibitory involvement, as ultimately the group of 
cells affected may define the disease.  
This study aimed to not only determine the validity of findings from the SOD1G93A model in Chapter 
2, but also to extend upon our earlier work by determining the relationship of interneuron pathology 
with clinical profiles of patients and the pattern of interneuron involvement with pyramidal neuron 
loss, since this may be relevant to our understanding of the mechanisms of cell death. This pilot 
study was performed in a small case group with immunohistochemistry utilised in post-mortem ALS 
cases and control subjects to determine if end-stage pathology in the SOD1G93A motor cortex was 
also present in the ALS motor cortex, and consequently establish the validity of an underlying CR- 
and NPY-interneuronal phenotype in patients. To assess pyramidal pathology in ALS cases, labeling 
was performed against the non-phosphorylated epitope in neurofilament H using the antibody SMI32 
as it preferentially binds to both pyramidal and motor neurons (Morrison et al 1987, Del Rio & 
DeFelipe 1994, Dzaja et al 2014).     
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3.2 METHODS 
3.2.1 Human tissue 
All cases were provided by the Victorian Brain Bank Network Australia. Informed consent for the 
collection of material was obtained prior to death and tissue use was approved by the University of 
Tasmania Human Ethics Committee and complies with the guidelines of the National Health and 
Medical Research Council (Permit #H0016154). All material had been previously de-identified. 
Blocks of primary motor cortex were provided as 10% formalin fixed blocks with post-mortem 
intervals ranging from 7-45 hours. Neuropathologist Professor Catriona McLean performed gross 
dissection. Human tissue was obtained from six patients with clinically defined ALS (age 68.81 ± 
6.3 years, M = 4, F =2) and six age-matched controls without neurological symptoms (age 66.16 ± 
8.5 years, M = 4, F = 2). See Table 3.1 for case characteristics.  
3.2.2 Histology and Immunoperoxidase labelling of postmortem human brain tissue 
Forty micrometre thick cryostat sections were cut from frozen (-14oC) optimal cutting compound-
embedded blocks of postmortem human brain tissue (Leica CM 1850 cryostat), previously 
cryoprotected by sequential exposure to increasing concentrations of PBS/Sucrose (4%, 16%, 
30%). Sections were stored at 4oC in 0.01M PBS containing 0.1% w/v sodium azide (Sigma 
Aldrich, Australia) and prior to immunostaining were washed in 0.01M PBS (3 x 10 min). Human 
tissue was processed as free-floating sections using the immunoperoxidase method, with 3,3’-
diaminobenzidine tetrahydrochloride (DAB) as the chromagen. Endogenous peroxidase activity 
was quenched with 0.3% hydrogen peroxide (H2O2) in methanol for 20 min to reduce background 
staining. Phosphate-buffered saline was used to all washes (3 x 10 min between each serum). Non-
specific immunoglobulin (IgG) binding of the tissue was blocked by 3% normal horse serum in 
phosphate-buffered saline for 30 min. Primary antibodies were diluted in 0.6% Triton X-100 at 
room temperature with gentle agitation for 24 hrs (Calretinin, 1:500, Swant; Calbindin, 1:500, 
Millipore; Neuropeptide Y, 1:500, Abcam; SMI32, 1:500, Bioscience). For visualization of 
immunopositive elements, sections were incubated with either biotinylated secondary antibodies 
(goat anti-rabbit or anti-mouse IgG, Vector, 1:200) for 90 min, followed by avidin-biotinylated 
horseradish peroxidase complex (1:250, Vector, 45 min), or where appropriate, the peroxidase-
polymer-based method with an HRP labelled polymer directly conjugated to the secondary 
antibody (goat anti-rabbit-IgG-HRP or anti-mouse-IgG-HRP, EnVision+ System, DAKO). The 
polymer-peroxidase system does not contain avidin or biotin, eliminating non-specific staining 
  
Table 3.1.  Human brain cases utilised for immunohistochemistry and analysis  
Type Age Gender Cortical Region PMI Site of onset Duration Family History 
Control        
1 73.7 F MC  26.5    
2 52.1 M MC 33    
3 75.9 M MC 50    
4 63.9 M MC 68    
5 67.3 F MC 24    
6 64.1 M MC 24    
ALS        
7 74.4 F MC 7 Left leg, arm & bulbar ~ 3.16 Unknown 
8 62 M MC 12.5 Right leg ~ 4.75 Unknown 
9 78.1 M MC 13.5 Bulbar (speech) ~ 3.5 Unknown 
10 63.9 M MC 14 Global (lumbar) ~ 2 Unknown 
11 69.3 F MC 45 Right leg ~ 3 Strong 
12 65.2 M MC 13.5 UMN involvement ~ 3 Unknown 
 
Post mortem interval (hours), age of death and sex is noted for all cases. Where applicable MND disease 
duration (years), site of onset and family history is noted. MC, Motor cortex. 
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resulting from endogenous avidin-biotin. All sections were developed with DAB as the 
chromogen (Peroxidase substrate kit, Vector) until adequate staining had been achieved.  
Sections were counterstained with haematoxylin (Peters 2010) to visualize cell nuclei, cell layers 
and the gray/white matter border within cortical regions. Briefly, sections were mounted on 
electrostatically charged slides (Flex, IHC microscope slides, Dako), stained with Mayer’s 
haematoxylin (30 sec), washed in running tap water (5 min), blued in ammoniated water (30 sec) 
and washed in running water (5 min). Sections were then dehydrated through graded ethanol (75% 
EtOH, 95% EtOH, 1x2 min; 100% EtOH, 2x2 min) cleared in xylene (3x2 min) and mounted in 
DPX (Koch-light Lab Ltd, England). No primary and secondary antibody controls were processed 
in vehicle solutions to control for non-specific labelling and residual endogenous peroxidase 
activity.  
3.2.3 Double immunolabelling for calretinin/SMI32 
The protocol was similar to that described above for single immunostaining. After blocking the 
endogenous peroxidase activity with 0.3% H2O2 and the non-specific IgG binding with 3% normal 
horse serum, the sections were first incubated in primary antibody against calretinin (1:500, 
SWANT) for 24 hours at room temperature. Sections were incubated in EnVision-HRP secondary 
antibodies (goat anti-rabbit-IgG-HRP, EnVision, DAKO). In this case, calretinin was developed 
using DAB as a chromogen intensified with ammonium nickel-sulphate and cobalt chloride (0.1g 
in 10ml H20) (DAB-Ni-CoCl2, blue/black reaction product) (Hsu & Soban 1982). After the first 
immunostaining, the sections were washed extensively in phosphate-buffered saline and re-
blocked for residual peroxidase activity and non-specific binding. The sections were then 
incubated in monoclonal mouse anti-SMI32 (1:500, Covance) for 24 hours at room temperature. 
After incubation in the HRP anti-mouse IgG secondary the second immunoperoxidase reaction 
was developed with DAB as the chromogen (brown reaction product). Sections were then 
dehydrated, cleared and mounted in DPX, as above. The immunopositive profiles at the light 
microscopic level were identified by their colour difference (i.e. calretinin-positive profiles were 
blue/black; the SMI32-positives were brown).    
3.2.4 Imaging and Quantification  
For quantitative purposes, all haematoxylin and immunostained DAB sections were analysed at 
the light microscopy level using an integrated stereology-brightfield system. Sampling was done 
using the Olympus BX-53 photomicroscope equipped with a Ludl X,Y motorized stage driven by 
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ProScan™III H31 controller (Prior Scientific, USA). The Visiopharm Integrator System 4.5.6.440 
(Visiopharm, Hoersholm, Denmark) was used to quantify the density of DAB labelled cells in the 
primary motor cortex using the physical dissector technique (Foster et al 2014). Contours were 
drawn to delineate the gray matter (layers I-VI) from the white matter as visualized with 
haematoxylin staining. Counting was performed using a 20x objective (N.A. 0.75) and a counting 
frame 200 x 200 µm was systematically moved through all counting areas until the entire 
delineated area was sampled. Identical quantification parameters were used in all sampling. For 
each individual case and control, three representative sections were counted per cortical region 
and numbers used to generate an average value. Six ALS cases and controls were used for each 
analysis where possible. However, due to limited tissue availability, one ALS case was excluded 
from the Calbindin interneuron analysis. Data is reported as number of cells per mm2. All cell 
counts were performed blinded to case status. Representative images were captured using a Zeiss 
LAB.A1 microscope with a 63x (N.A. 0.85), 40x (N.A. 0.65), 20x (N.A. 0.45) and 10x (N.A. 
0.25) objective using Zen 2 software (Zeiss, Germany) and the digital AxioCam ICc 5 camera 
(Zeiss, Germany). Photomicrographs were processed using Adobe Photoshop CS6 (Version 13.0, 
USA).  
3.2.5 Statistical analysis 
Data was analysed using one-way ANOVA and using non-parametric two-tailed Students t tests. 
Statistical significance was set at P < 0.05. Average values were expressed as means ± standard 
error of mean. To examine individual-level relationships between the cell densities of neuronal 
populations assessed, a non-parametric Pearson’s correlation r2 was reported. Multiple regression 
analysis was used to determine if ALS case characteristics were predictors of neuronal densities 
(SPSS, Version 20). For comparisons of clustering between ALS cases and controls, cluster 
analysis (k-means) was performed (SPSS) with cluster number cross-validated with the 
Hierarchical Cluster Ward’s method (Ward 1963, Kaufman & Rousseeuw 1990).  
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3.3 RESULTS 
3.3.1 Optimisation of neuron labelling in post-mortem human tissue sections 
Immunohistochemical labelling of human tissue was conducted using an immunoperoxidase-
enzyme linked detection method. While immuno-fluorescence produced a high signal to noise 
ratio in mouse cortical sections, in human tissue labelling appeared indistinct and there was a high 
level of background. This was primarily due to autofluorescence caused by formalin fixation of 
human tissue and age-related pigment lipofuscin, which masks the primary signal (Figure 3.1 a). 
As a result, a light based immunoperoxidase detection method was used for all neuron labeling as 
it produces a coloured precipitate, that could be visualised by a light microscope, thus avoiding the 
non-specific signal that is otherwise detected using fluorescent microscopy (Figure 3.1 b). The 
optimal immunolabeling conditions were determined by trialing different primary antibody 
incubation times, different temperatures of incubations and by serial dilutions of primary antibody 
concentrations. After adequate labeling was established, the coloured chromagen precipitate was 
optimised to ensure a distinct and clear signal could be captured with the light microscope (Figure 
3.1 c). A brown DAB precipitate was used for single labeling experiments and the chromagen 
developed to allow sufficient contrast with the blue haematoxylin nuclei staining (Figure 3.1 d). 
For double labeling experiments both DAB-Nickel (black) (Figure 3.1 e) and DAB-Nickel-
Cobalt-Chloride (blue) were trialed against DAB. The blue DAB-Nickel-Cobalt-Chloride was 
chosen for double labelling as it produced a clear, distinct and less saturated signal that could be 
co-localised with DAB (Figure 3.1 f). To determine if endogenous immunoperoxidase activity 
was adequately quenched, and labeling observed was only due to binding of the secondary 
antibody, no primary and no secondary controls were performed (Figure 3.1 g-h).  
3.3.2 Calretinin-immunoreactive neurons are reduced in the ALS patient motor cortex  
To investigate whether, the interneuron phenotype we observed in the SOD1G93A mouse model of 
ALS reflects interneuron vulnerability relevant to human disease, we immunolabeled sections 
from the motor cortex of ALS patients and age-matched controls. In control tissue, CR-expressing 
neurons were small- and medium-sized aspiny bipolar cells with clear processes visible (Figure 
3.2 a, c). In contrast, examination of the ALS motor cortex showed fewer CR-expressing cells in 
layers II-III and labelled processes appeared blebbed and beaded (Figure 3.2 b, d). Quantitation 
confirmed this observation, revealing a significant decrease in the density of CR-expressing 
interneurons in a subset of ALS cases in layer II-III of the motor cortex (Figure 3.2 e). 
Hierarchical cluster analysis demonstrated the presence of two distinct clusters of ALS cases when 
  
 
 
 
 
 
 
 
Figure 3.1. Optimisation of human tissue labelling  
a-c, Representative images of interneuron labelling in post-mortem cortical sections 
from human tissue. a, Immunohistochemical labelling of interneurons with fluorescent 
based labelling techniques shows a lack of specificity and clarity in human tissue, with 
high levels of autofluorescence and fluorescent lipofuscin granules visualised. b, An 
immunoperoxidase-enzyme linked method has an improved signal to noise ratio as auto 
fluorescence and fluorescent age-related lipofuscin granules are avoided. c, 
Immunoperoxidase labelling protocols produce a clear signal once optimised for 
antibody concentrations, non-specific binding and endogenous peroxidase activity. d-f, 
Images show optimisation of chromagen for neuron labelling. d, The brown chromogen 
DAB is chosen for single labelling protocols and for counterstaining with 
Haematoxylin. e, For double-labelling protocols the black chromogen DAB-Nickel (e) 
is too dark to assess co-localisation with DAB labelled neurons. f, The blue chromogen 
DAB-Nickel-Cobalt-Chloride (f) produces a lighter labelling more appropriate for co-
localisation analysis with DAB labelled neurons. g-h, Representative images show no 
primary controls (g), and no secondary controls (h). Scale bar in (a-h) 25µm. 
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considering age, sex, disease duration and density of CR-expressing neurons. ALS Cluster 1 
comprised three ALS cases that were unchanged from controls (ALS 1, 108 ± 3 cells per mm2; 
Control, 99 ± 5 cells per mm2), while ALS Cluster 2 comprised a further three cases that showed a 
significant decrease in CR-expressing neurons (~29%) compared to controls (ALS 2, 70 ± 3 cells 
per mm2, p < 0.006). A multiple regression analysis was performed to discount the possibility that 
CR-pathology was a consequence of age, post-mortem interval, sex or disease duration (Table 
3.2). However, independent variables did not account for the alteration in CR cell density 
identified in layer II-III of the motor cortex in the subset of ALS cases. Interestingly, a strong 
family history of ALS was present in one case from ALS Cluster 2, which may indicate a genetic 
component influences the extent of CR-density in cases. However, the full genetic history of cases 
was unavailable to investigate a genetic contribution to pathology. Nonetheless, these results 
suggest a differential involvement of CR-interneurons in ALS cases, with interneurons preserved 
in some cases and reduced in others.  
3.3.3 NPY-immunoreactive neurons are increased in the ALS patient motor cortex  
NPY-interneuron pathology was evaluated to determine cell type specific changes in the ALS 
motor cortex. In control tissue NPY-expressing interneurons were small aspiny bipolar and 
multipolar cells with fine processes (Figure 3.2 a, c). In contrast, NPY-expressing interneurons 
were densely labelled in ALS cases and there was a distinct increase in the extent of NPY 
immunoreactive fibers present in all layers of cases examined. Often, NPY intensely 
immunoreactive fibers were beaded and formed small clusters throughout the cortex that appeared 
unrelated to the distribution of NPY-expressing interneurons (Figure 3.2 b, d). Analysis revealed 
that the density of NPY-expressing interneurons was significantly increased (~200%) throughout 
the entire motor cortex compared to controls (ALS, 0.6 ± 0.1 cells per mm2; Control, 0.3 ± 0.04 
cells per mm2) (p < 0.05, students t test) (Figure 3.2 e). There was no significant correlation 
between the density of NPY-interneurons and age, sex, post-mortem interval, or disease duration; 
however, it was interesting to note that the cases with the greatest increase in NPY-expressing 
interneurons compared to controls had the greatest preservation of CR-interneurons in ALS cases 
(ALS Cluster 1). Likewise, ALS cases with the least increase in NPY-expressing neurons had the 
greatest loss of CR-interneurons (ALS Cluster 2).  
3.3.4 CB-expressing interneurons are unchanged in the ALS patient motor cortex  
To determine if this pathology was generalised to calcium-binding proteins, or recapitulates the 
subtype-specific CR pathology identified in the SOD1G93A model, we assessed CB-expressing 
  
 
 
 
 
 
 
 
 
Figure 3.2. Calretinin-expressing interneurons are reduced within the 
supragranular motor cortex of ALS cases.  
Coronal sections of motor cortex from post-mortem control and ALS cases were 
labelled for CR-expressing interneurons. a-b, Representative images show CR-
expressing interneurons in a control (a) and ALS case (b) labelled with DAB (brown) 
and nuclei stained with Haematoxylin (blue). c-d, High magnification images show 
normal bipolar and multipolar CR-expressing interneurons in control (c) motor cortex 
and abnormal CR-expressing interneurons with blebbed and beaded processes 
(highlighted with arrows) in ALS (d) motor cortex. e, CR-interneuron density was 
quantified within the supragranular lamina (layers II & III) of the motor cortex. Based 
on CR-interneuron density ALS cases clustered into two sub-groups as determined by 
Hierarchical Cluster Ward’s method. ALS Cluster 2 had significantly reduced CR-
interneuron density compared to controls (***P < 0.0005, unpaired Student’s t test). 
Scale bar in (a-d) 25µm.  
 
  

 
  
Table 3.2. Multiple regression analysis of CR-density in human motor cortex    
Dependent Variable Beta t-value P VIF Adj R2 F p 
CR-density Age 0.334 0.2 0.875 1.246 0.016 1.020 0.622 
 PMI 0.023 0.029 0.982 1.404    
 Sex -32.16 -1.374 0.400 1.613    
 Duration 10.15 0.942 0.519 1.029    
 
Age, post-mortem interval (PMI), sex and duration of disease were not significant predictors of 
CR-density in the motor cortex of ALS cases and controls (P > 0.05). A model fit (adjR2) <0.1 
suggests other independent variables may influence CR-density, as a variance inflation factor 
(VIF) of less than 2.5 is found for each independent variable. 
  
 
 
 
 
 
 
 
Figure 3.3. Neuropeptide Y-expressing interneurons and fibres are increased 
within the motor cortex of ALS cases.  
a-b, NPY-expressing neurons were labelled in the motor cortex of ALS cases and 
controls using immunoperoxidase DAB staining (brown). a, Layer II & III of the motor 
cortex of a normal control case shows intricate labelling of NPY-expressing neurons. b, 
In ALS cases immunoreactive fibre density is increased and neurons are irregular with 
prominent labelling as visualised in higher magnification images (arrows). c-d, 
Representative images show NPY-expressing neurons in control (c) and ALS cases (d) 
with neuronal nuclei counterstained with Haematoxylin (blue). High power view shows 
nuclei are visible in NPY-expressing neurons in controls (cii, ciii) while in ALS cases 
neurons have intense somatic NPY-labelling and beaded neurites (arrows) throughout 
tissue (dii, diii). e, The mean density of NPY-expressing neurons was significantly 
increased throughout the motor cortex (layers I-VI) in ALS cases compared to controls 
(*P < 0.05, unpaired Student’s t test). Scale bar in low and high magnification images 
(a-d) 50µm.  
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interneurons in layers II-III of the motor cortex. CB-expressing interneurons were predominantly 
medium sized bipolar and multipolar cells with complex dendritic trees visible (Figure 3.4 a, c). 
In ALS cases there was no overt differences in the appearance of CB-expressing interneurons 
(Figure 3.4 b, d). Analysis confirmed that the density of CB-expressing interneurons was 
unchanged compared to controls (ALS, 73 ± 7.6 cells per mm2; Control, 71 ± 7.7 cells per mm2) 
(p < 0.05, students t test) (Figure 3.4 e). There was no significant correlation of CB-interneurons 
with age, sex, post-mortem interval, or disease duration. These results indicate that CB-expressing 
interneurons are not affected in a similar manner to the CR-expressing interneurons in layers II-III 
of the ALS motor cortex.  
3.3.5 Interneuron density in the ALS patient motor cortex is associated with SMI32 
pyramidal cortical neuron pathology in ALS patients.  
To determine if interneuron pathology was associated with cortical motor neuron pathology, 
SMI32-labeling was used to visualise the large pyramidal neurons in layer V (Campbell & 
Morrison 1989, Nihei et al 1993) in cases compared to controls. In control tissue large pyramidal 
populations were prominent in layers III and V (Figure 3.5 a, c, e), while in ALS cases the 
SMI32-expressing pyramidal neurons in layer V were atrophic and appeared to be decreased in 
density, particularly the medium and large SMI32-expressing neurons (Figure 3.5 b, d). 
Quantitation revealed that cases with the greatest reduction in SMI32-expressing pyramidal 
neurons in layer V had the greatest reduction in CR-expressing interneurons in the layer II-III of 
the motor cortex (ALS Cluster 2). Interestingly, the ALS cases that showed no alteration of CR-
expressing interneurons (ALS Cluster 1) also showed minimal SMI32 pathology. Indeed, there 
was a strong and significant correlation between the density of SMI32-expressing pyramidal 
neurons from layers V and the density of CR-expressing interneurons from layers II-III within the 
ALS motor cortex (r2 0.702, P <0.001) (Figure 3.5 g). Similarly, there was also a positive 
correlation between the density of NPY-expressing interneurons and the density of SMI32-
expressing pyramidal neurons in ALS cases (r2 0.690, P <0.05) (Figure 3.5 h). However, this 
correlation was not significant in controls, suggesting that this relationship is particular to the ALS 
cortex. Again, it was interesting to observe that the cases with the greatest increase in NPY-
expressing interneurons compared to controls had the greatest preservation of CR-interneurons in 
the ALS cases, and also the least amount of SMI32-pyramidal neuron loss. Indeed, while there 
was no correlation between CB-expressing interneurons and SMI32-expressing pyramidal neurons 
(r2 0.166, P >0.05) (Figure 3.5 i), there was in fact a correlation between the extent of CR-
expressing interneurons and the extent of NPY-expressing interneurons (r2 0.672, P <0.05) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Calbindin-expressing interneurons are unchanged within the motor 
cortex of ALS cases.  
Cells expressing CB were labelled in the motor cortex of ALS cases and controls using 
immunoperoxidase DAB staining (brown) and counterstained with Haematoxylin 
(purple). a-b, Representative images show CB-expressing interneurons in layer II & III  
of the motor cortex of a control (a) and ALS case (b). c-d, High power images show 
clear labelling of CB-expressing interneurons and processes in controls (c) and 
comparable labelling in ALS cases (d). e, The mean density of CB-expressing 
interneurons was unchanged in layer II-III of the motor cortex in ALS cases compared 
with controls (P > 0.05, unpaired Student’s t test). Scale bar in all low and high 
magnification images (a-d) 25µm.  
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(Figure 3.5 j). This may indicate that the vulnerability of the ALS motor cortex is associated with 
the extent of CR-, NPY- and SMI32-populations.  
It is important to note that large spiny excitatory CR-neurons can be found in the mammalian 
cortex (Del Rio & DeFelipe 1997, Liu et al 2014), as well as the non-spiny smaller typically 
inhibitory populations. As such, SMI32/CR double labeling was performed to confirm that the 
change in CR-interneuron density in layer II-III is primarily associated with inhibitory aspiny 
interneurons, and the change in SMI32 density in layer V is not confounded by the excitatory 
spiny CR-population. In both cases and controls, less than 1% of cells labeled were found to be 
spiny excitatory cells (Figure 3.5 f), and none of these cells were located in layer II-III, nor did 
they differ in density between controls and ALS cases (Figure 3.5 k). The combined results of 
these experiments demonstrate that reduced interneuron cell density is present in a subset of ALS 
cases, is specific to aspiny CR interneurons, and correlates well with the extent of the change in 
NPY and SMI32 cell density.  
  
  
 
 
 
 
 
 
 
 
 
Figure 3.5. SMI32-immunoreactive pyramidal neurons are reduced in the ALS 
motor cortex and correlate with interneuron density.  
Neurons expressing SMI32 were labelled in the motor cortex of ALS cases and 
controls using immunoperoxidase DAB staining (brown). a-b, Representative images 
show SMI32-labelled pyramidal cells in the motor cortex in control (a) and ALS cases 
(b) with double labelling performed to visualise CR-expressing interneurons using 
DAB-Nickel-Cobalt Chloride (blue). c-d, In control motor cortex pyramidal neurons 
are normal (c), while in ALS tissue (d) cells appear atrophic and decreased in number 
with condensed nuclei visualised by Haematoxylin (purple). e, High magnification 
images show large Betz cells in control tissue with dendritic branches leaving from the 
entire circumference of the soma. f, A spiny double-labelled SMI32 and CR-expressing 
cell in layer V of the motor cortex (i) and a normal non-spiny CR-expressing 
interneuron (ii). g-j, Pearson’s correlation analyses revealed positive correlations 
between the density of SMI32-expressing neurons, CR-expressing interneurons (g) and 
NPY-cells (h), but not between the density of SMI32-expressing neurons and CB-
expressing interneurons (i), while CR-interneuron and NPY-cell density (j) is 
associated (*P < 0.05, Pearson’s correlation r2). k, Analyses shows a small proportion 
of large spiny CR-expressing cells are present in the cortex relative to non-spiny small 
CR-expressing interneurons, and are unchanged between controls and cases (P < 0.05, 
one-way ANOVA). Scale bar in (a-f) 50µm.  
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3.4 DISCUSSION 
In the ALS cortex, there is clinical evidence that the disease may be potentiated by dysfunction, 
degeneration or loss of inhibitory interneurons (Ziemann et al 1997, Martin & Chang 2012, Turner & 
Kiernan 2012). The previous findings from this thesis support the involvement of specific inhibitory 
populations, however, it was unknown if this was relevant to the human disease and how these 
populations may be implicated in the context of the ALS motor cortex. In this small pilot study 
investigations were performed to identify specific changes in subclasses of GABAergic interneurons 
that were previously identified in the SOD1G93A mouse. Additional analyses were performed to 
compare the relationship of interneuron pathology in the ALS motor cortex to the clinical profile of 
cases, and the pattern of interneuron involvement with pyramidal neuron loss. The current chapter 
advances our understanding of the selective vulnerability of interneurons in ALS and the potential 
cellular basis of functional imaging abnormalities reported in clinical studies.  
3.4.1 The pattern of neuron loss in the ALS motor cortex  
In ALS, traditional neuropathological techniques have been used to show that neuronal degeneration 
occurs frequently in the motor cortex. The most prominent changes reported are loss of the giant 
layer V pyramidal Betz cells and astrocytic gliosis (Brownell et al 1970, Udaka et al 1986, Nihei et al 
1993, Nagy et al 1994). In this study, there is loss of the medium to large SMI32 cells. However, 
relatively less is known about the involvement of other neuronal populations in the motor cortex, 
particularly the inhibitory interneurons.  
In the current investigation comparison of the brains of ALS patients and control subjects revealed 
changes in CR and NPY interneurons that largely recapitulated the interneuron pathology observed 
in the SOD1G93A mouse model. Similarly, CB-interneurons were found to be unaltered, which agrees 
with findings from the SOD1G93A study and a previous study in the ALS cortex (Ince et al 1993). 
However, there is a distinct difference in the extent of interneuron pathology in cases, exemplified by 
a significant loss of CR-expressing interneurons in 50% of ALS cases. While previous studies have 
reported a trend towards a decrease in the density of CR-interneurons in the ALS primary motor 
cortex, it was not clear if a similar clustering pattern was observed (Maekawa et al 2004).  
More relevant to the current study, a recent investigation found a distinct divergence of interneuron 
pathology in the cortex of Huntington’s disease patients (Kim et al 2014b). While heterogeneity was 
predominately centred on a differential loss of CB-interneurons, it was found that heterogeneity was 
associated with the symptom subtype exhibited by individual cases. Patients with dominant motor 
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symptoms had a loss of CB-interneurons, while no interneuron loss was observed in the primary 
motor cortex of cases with major mood disorder. This may indicate that the divergence in CR-
pathology observed in this study may relate to the extent of motor and cognitive involvement in the 
cortex of ALS cases, particularly as the disease is now considered on a spectrum with frontotemporal 
dementia. However, due a lack of clinical information in this study we were unable to discern such 
an association and as such it cannot be ruled out as a cause of heterogeneous pathology. Moreover, 
while considerable evidence suggests that variable interneuron dysfunction may be linked to altered 
disease duration in the ALS motor cortex, in this study no associated with duration of disease, nor 
with age, gender or post-mortem interval is demonstrated in relation to interneuron involvement. 
However, due to a small sample size, such a correlation cannot be excluded and it will be important 
for future studies to explore such an association with an increased sample size. Nonetheless, the 
examination of cell morphology in this study showed major differences in the CR-interneuron 
populations, such as blebbing and beading of processes in ALS cases, which support their 
involvement in disease.  
3.4.2 Relationship of heterogeneous interneuron pathology to pyramidal neuron loss 
Interneurons are essential components of the cortical motor neuron network and may be central to 
network failure. Every segment of a pyramidal neuron, such as soma, dendritic branches and spines, 
and the initial axonal segment, receives dense GABAergic synaptic innervation [see reviews (Jones 
1993, Buzsaki et al 2004)]. In ALS, clinical imaging studies suggest brain plasticity in motor 
networks is correlated with disease progression (Poujois et al 2013), and the extent of inhibitory 
alteration in the motor cortex is associated with increased excitability of the motor cortex (Menon et 
al 2014, Geevasinga et al 2015, Shibuya et al 2016). Hence, this study was interested in determining 
if such a correlation may be found in the interneuron and pyramidal pathology in the region.  
The results of this study show a correlation between differential loss of CR-interneurons in the 
primary motor cortex and pyramidal neuron pathology. That is, in the primary motor cortex of ALS 
cases, the selective loss of CR-interneurons was associated with pyramidal neuron loss, measured by 
decreased density of layer V pyramidal neurons. Intriguingly, the converse was also shown with 
preservation of CR-interneurons associated with a lesser extent of pyramidal neuron pathology. This 
suggests that interneuron pathology and corticomotoneuronal pathology may be coupled in the ALS 
motor cortex. However, as CB-interneuron pathology is not associated with pyramidal neuron 
pathology, this indicates vulnerable networks may be associated with specific interneuron 
populations, such as the CR-interneurons.  
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From a functional view point, when looking at other diseases with demonstrated reductions in CR-
interneurons, it is most interesting to find that in the epileptic human hippocampus the number of 
CR-cells lost also correlated with the severity of principal cell loss in the region (Toth et al 2010). 
This common neurological condition is by definition due to abnormal excessive or synchronous 
neuronal activity in the brain (Fisher et al 2005), which when comparing evidence for 
hyperexcitability in the motor cortex in ALS draws certain parallels. Thus, when considered in the 
context of ALS, this may suggest a pathogenic feedback mechanism whereby the loss of CR cells 
translates to a loss of principal cells, or vice verse. Additionally, it may also indicate that reduced CR 
populations are involved in a loss of circuitry control, contributing to the hyperexcitability observed 
in ALS, and epilepsy.  
While it remains to be determined if CR-populations drive corticomotoneuronal degeneration, or 
respond to altered network feedback due to corticomotoneuronal degeneration, the differential nature 
of CR pathology in patients is not surprising. Previous literature has established that the extent of 
pyramidal neuron pathology in layer V of the motor cortex varies between patients (Nihei et al 1993, 
Maekawa et al 2004), as also observed in this study. Therefore, it was quite unexpected that there 
was an overall significant increase in NPY interneurons throughout the entire motor cortex of all 
ALS cases. However, in line with the clustering of ALS cases based on CR-interneuron pathology, it 
was an interesting observation to find that cases with the least amount of pyramidal and CR-
pathology had the greatest increase in NPY cell density relative to controls. Indeed, this study shows 
a correlation of NPY-pathology with both pyramidal pathology and CR-pathology. This suggests that 
while CR-interneuron pathology may be detrimental in the motor cortex, increased NPY may be 
associated with a reduced extent of cortical damage. However, this correlation was only found in 
ALS cases, not controls, suggesting this may be a compensatory mechanism specifically related to an 
altered network in the ALS motor cortex. This may be supported by the apparent marked increase in 
NPY-immunoreactive fibres identified to varying degrees in all ALS motor cortices studied.  
When considering the distinct morphological appearance of NPY-immunoreactive fibres in the ALS 
cortex, again similar parallels are observed with key-disease affected regions in the epileptic brain. 
Previous studies have shown an increase in the cell density and length of NPY immunoreactive 
fibres in hippocampal subfields with sclerosis in the epileptic human hippocampus (De Lanerolle et 
al 1989, Mathern et al 1995, Furtinger et al 2001), which mirror the NPY pathology detected in the 
present study. The striking similarity of this pathology is best demonstrated when directly comparing 
photomicrographs from works of Furtinger and colleagues (Furtinger et al 2001) with images from 
the present study (Figure 3.6).  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. NPY-immunoreactive fibres in the epileptic human hippocampus 
parallel NPY-pathology demonstrated in the ALS motor cortex.  
a, Widespread NPY immunoreactivity is shown in a patient with hippocampal sclerosis 
as demonstrated by Furtinger and colleagues in 2001. b, Striking similarities are 
demonstrated in the NPY-immunoreactive fibres found in the ALS motor cortex in this 
study. High magnification images in both show the unusual pattern of NPY process 
labelling in both disease-associated regions. Scale bar in (a-b) 50µm. 
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While the mechanism responsible for NPY involvement in ALS is not yet known, it is tempting to 
speculate that this may again represent a mechanism related to increased excitability. Regarding 
modes of NPY expression, in normal neurological conditions NPY is contained and released by 
GABAergic interneurons, however in regions of pathogenically enhanced excitability it can be found 
upregulated in interneurons and aberrantly expression in non-neuronal populations (Marksteiner et al 
1990, Rizzi et al 1993, Gruber et al 1994). This has been typically demonstrated in the hippocampus 
of mouse and rat strains that are susceptible to seizures, with NPY transiently upregulated in 
interneurons and granule cells/mossy fibres of the dentate gyrus from the pre-convulsive stage in 
animals (Schwarzer et al 1996, Vezzani et al 1996). Thus, it is possible that NPY-fibre 
immunoreactivity in this study may represent upregulation of the neuropeptide on either GABAergic 
or glutamatergic processes. While we confirm that CR-interneuron involvement is restricted to 
aspiny inhibitory SMI32 negative populations, future studies should also conduct co-localisation for 
equal assessment of NPY labelling. Hence while we cannot rule out the upregulation of NPY on 
pyramidal populations, it is important to note that irrespective of the mode of delivery, 
administration of NPY has been found to potently suppress epileptic activity in hippocampal slices 
from epilepsy patients (Patrylo et al 1999). Therefore, the demonstrated alteration of NPY reported 
here should remain of high interest in the context of cortical hyperexcitability demonstrated in the 
motor cortex of ALS patients. 
3.4.3 Conclusion 
Comparing the brains of ALS patients with control subjects revealed specific changes in CR and 
NPY interneurons that largely recapitulated the interneuron pathology observed in the SOD1G93A 
mouse model. However, a novel divergence of interneuron pathology across ALS patients identified 
heterogeneity in disease pathology, as demonstrated by the significant loss of CR-expressing 
interneurons in 50% of ALS cases. Nonetheless, the clear increase of NPY-expressing neurites in 
ALS cases and increased cell density supports a similar pathogenic process in the motor cortex of 
ALS patients and the SOD1G93A mouse model that warrants further investigation. Indeed, while 
future studies are required to fully elucidate the relationship of interneuron pathology with clinical 
characteristics of individual cases due to low case numbers, the results from this study suggest that 
both CR and NPY interneuron populations may have an important role to play in the ALS motor 
cortex. This study proposes that CR and NPY may be critical determinants of altered excitability in 
the ALS cortex, due to profound similarities with the epileptic human cortex. The divergence of 
pathology between cases may indicate innate differences/vulnerabilities in the cortex that may be 
associated with the extent of cortical dysfunction. Whether this relates to variable disease 
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progression rates in patients remains to be determined, however, due to the correlation with 
pyramidal pathology this may be of interest for future studies. Moreover, the differences in cases 
may highlight the potential for therapeutic intervention aimed at modulating these populations to 
restore or maintain network functions. 
 
 
  
 
 
 
 
 
 
 
Chapter 4 
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4 THE SOD1G93A MUTATION ALTERS CORTICAL INTERNEURON DEVELOPMENT AND 
INTRINSIC ELECTRICAL PROPERTIES IN VITRO IN MOUSE MODEL OF ALS  
4.1 INTRODUCTION 
It is increasingly apparent that a long pre-clinical and pre-symptomatic period may exist in ALS 
patients, in which underlying pathogenic processes initiated much earlier in life, may remain 
innocuous until protective and compensatory mechanisms that mask primary pathogenic events 
become overwhelmed or saturated, culminating in the ALS phenotype [see review (Eisen et al 
2014)]. Evidence for this relates to the identification of pathological changes in animal models 
shortly after birth, predating the first clinical abnormalities by 2-3 months (Bendotti et al 2001, 
Ozdinler et al 2011, Jara et al 2012, Vinsant et al 2013), and more recently, the detection of cortical 
hyperexcitability in sporadic and familial ALS patients months prior to measurable lower motor 
signs or symptoms (Menon et al 2014). In familial ALS, these early pathogenic processes may be 
initiated by the expression of mutant proteins during early embryonic life. Indeed, investigation of 
one of the most well documented familial mutations, the SOD1G93A mutation, has demonstrated 
increased motor neuron excitability during early postnatal development in vitro (Pieri et al 2003, 
Kuo et al 2004) and prior to symptom onset in vivo (Fogarty et al 2015). This indicates that there is 
likely underlying bio-molecular dysfunction occurring in ALS patients throughout life, but also that 
compensatory mechanisms may mask these early alterations for months in ALS mouse models, and 
potentially for decades in humans.  
In the context of previous findings from this thesis, this raises the question of whether changes in 
interneurons are casual and/or adaptive in nature. When considering this first possibility it is 
important to note that while mutant SOD1G93A has been shown to cause intrinsic damage to motor 
neurons, expression in motor neurons alone is reportedly insufficient to cause disease (Clement et al 
2003), supporting the view that the disease pathogenesis is critically dependent on dysfunction of 
other cell types (Boillee et al 2006a, Ilieva et al 2009). Indeed, SOD1 is ubiquitously expressed in all 
cells of the CNS throughout life (Gurney et al 1994), including interneurons, and while the intrinsic 
vulnerability of cortical interneurons has yet to be investigated in ALS, the intrinsic 
electrophysiological properties of cortical neuronal populations have been found to be altered in 
response to expression of the SOD1G93A mutation in vitro (Pieri et al 2009). However, as 
interneurons are primarily considered an adaptive cell type (Jones 1993, Mendez & Bacci 2011, 
Lehmann et al 2012) the alternate scenario may include the alteration of cortical interneurons 
secondary to changes in network excitability. Indeed, it is increasingly recognised that interneuron 
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development is an activity-dependent process (Cancedda et al 2007, De Marco Garcia et al 2011, 
Kepecs & Fishell 2014), and it is demonstrated that motor neuron hyperexcitability is present at both 
embryonic and presymptomatic stages in ALS models (Kuo et al 2004, van Zundert et al 2008, 
Martin et al 2013) and also in patient-derived motor neurons (Wainger et al 2014, Devlin et al 2015). 
Therefore, there is potential for interneuron dysfunction to initiate, or be responding to, changes in 
excitability during development. 
In order to investigate these possibilities, the current study aimed to determine if cortical interneuron 
development was impaired in the presence of the SOD1G93A mutation in vitro. For these analyses, 
complementary culturing, immunohistochemical and electrophysiological techniques were used to 
investigate the intrinsic electrical properties of cortical interneurons, as well as their structural 
maturation and normal development in vitro. To aid in the identification of cortical interneurons, WT 
and SOD1G93A transgenic mice were crossed with the Gad67-GFP mouse, which expresses a 
fluorescent green protein under the interneuron-specific glutamate decarboxylase 67 (GAD67) 
promoter (Tamamaki et al 2003). Primary cortical cultures were derived from E15.5 Gad67-
GFP::SOD1G93A and Gad67-GFP::C57Bl6 (WT) transgenic mice, as this represents an embryonic 
stage when cortical interneurons generated from both the caudal/lateral ganglionic eminence 
(Miyoshi et al 2010) and medial ganglionic eminence should be present in the cortex (Miyoshi et al 
2007).  
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4.2 METHODS 
4.2.1 Animals 
All procedures were approved by the Animal Ethics Committee of the University of Tasmania and 
conducted in accordance with the Australian Code of Practice for the care and Use of Animals for 
Scientific Purposes, 2013. Gad67-GFP knock-in transgenic mice were developed by Prof. Nobuaki 
Tamamaki (Kyoto University) (Tamamaki et al 2003) and were a kind donation form Prof. John 
Bekkers (ANU). These mice express green fluorescent protein (GFP) in GABAergic neurons arising 
from the ganglionic eminence under the control of the mouse Gad67 promoter, one of the two genes 
encoding isoforms of the GABA synthesizing enzyme, glutamic acid decarboxylase (Suzuki & 
Bekkers 2010a). These mice were intercrossed with the SOD1G93A mouse line (previously described 
in Chapter 2.2.1) purchased from the Jackson Laboratory (CA, USA), both maintained on a C57BL/6 
background, to generate double transgenic Gad67-GFP::SOD1G93A mice. Animals were bred at the 
University of Tasmania. Animals were housed in individually ventilated cages at 20oC, on a 12 hour 
light-dark cycle, with access to food and water ad libitum. Gad67-GFP transgenic littermates were 
used as controls.   
4.2.2 Primary neuronal cortical culture  
Primary mouse cortical neuron cultures were derived from individual mouse embryos, as previously 
described (Brizuela et al 2015). Briefly, Gad67-GFP and SOD1G93A transgenic mice were time 
mated, the pregnant females killed by CO2 exposure at 15.5 days of gestation, and the embryos 
removed. Genotyping of embryos for Gad67-GFP was performed by fluorescence imaging using 
470nm light on a Carestream Image Station 4000MM pro (Carestream Molecular Imagin, USA).  
Neocortical hemispheres were dissected from individual embryos, meninges removed and placed 
into 5ml Hanks Buffered Salt Solution (HBSS; Thermo-Fisher Scientific, USA). Cortical tissue was 
dissociated by enzymatic digestion with 0.025% w/v Trypsin at 37oC for 5min. The digestion was 
halted with the addition of 1ml of pre-warmed medium (NeurobasalTM supplemented with 2% v/v B-
27, 10% v/v fetal calf serum, 0.5mM L-glutamine, 25µM glutamate and 1% streptomycin penicillin; 
Thermo-fisher Scientific, USA). Tissue pieces were allowed to settle and after removal of the 
medium, dissociation was completed by resuspension of cells in 500µl of pre-warmed medium and 
gently triturated. Cell viability and concentration was assessed using trypan blue vital dye exclusion 
(Sigma-Aldrich, USA). Cortical neurons dissociated from individual embryos were then plated at a 
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density of 3.5 x 104 cells/mm2 on 19mm diameter glass coverslips, pre-coated with 0.001% poly-L-
lysine (Sigma-Aldrich, USA) in 0.01M PBS (pH 7.0).  
Twenty-four hours after plating, initial plating media was removed and replaced with serum-free 
growth medium (NeurobasalTM media, supplemented with 2% v/v B-27, 0.5mM L-glutamine and 1% 
streptomycin penicillin; Thermo-fisher Scientific, USA). This promoted the selective growth of 
neuronal populations (Brewer 1995). Half of the media was replaced every three to four days with 
fresh media. Cultures were maintained in a humidified incubator at 37oC in 5% CO2 for up to 15 
days in vitro (DIV). Cultures were either fixed at 3, 7, 10 or 14 DIV for synaptic analysis, or 10 DIV 
for interneuronal, electrophysiological and morphological assessments.     
4.2.3 Genotyping 
After single Gad67-GFP-positive embryos had been cultured, they were subsequently genotyped for 
the SOD1G93A transgene using a multiplexed quantitative polymerase chain reaction protocol (real-
time qPCR). DNA was extracted from either cortical tissue obtained at embryonic dissection, or from 
the mature genetically isolated cultures at 10-14 DIV, using an Extract-N-Amp Tissue PCR tissue kit 
(Sigma-Aldrich) according to the manufacturer’s instructions. The presence of the SOD1G93A 
transgene was assessed as previously described in Chapter 2.2.2, and copy number analysed in order 
to monitor genetic drift according to standard protocols (Leitner et al 2009).  
4.2.4 Electrophysiology 
Cortical neurons cultured on glass coverslips (10 DIV) were superfused at 24 ± 1oC with 
bicarbonate-buffered solution [155mM NaCl, 3.5mM KCl, 2mM CaCl2, 1.5mM MgCl2, 10mM 
glucose; osmolarity adjusted to 305-310mOsm/kg by the addition of D-sorbitol (all Sigma)]. For 
recordings, patch electrodes were prepared from borosilicate glass capillaries (1.5mm O.D. x 
0.86mm I.D.) (Harvard Apparatus, UK) and had a resistance of 7-9Ω when filled with a internal 
solution containing 130mM K-gluconate, 4mM NaCl, 10mM HEPES, 0.5mM CaCl2, 10mM 
BAPTA, 4mM MgATP, 0.5mM Na2GTP, set to a pH of 7.4 (KOH), and an osmolarity of 290 ± 5 
mOsm/kg with D-sorbitol. Whole-cell patch clamp recordings of GABAergic cortical interneurons, 
selected based on GFP expression, were collected using an Axopatch 200B amplifier (Molecular 
Devices, USA), with a holding potential of -70mV. Recordings were made using a gap free protocol 
for 3 minutes and 10 seconds, sampled at 10Hz and filtered at 5Hz using PClamp9.2 software 
(Molecular Devices). Access resistance was recorded before and after each recording. Data was not 
included if the cells access resistance was ≥ 15 MΩ, or if the access resistance changed by ≥ 10% 
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during the course of the recording. Access resistance did not significantly differ between groups. 
Voltage-gated sodium and potassium currents were evoked with a series of voltage steps (-70 to 
50mV, 10mV increments), and were analysed using the programs Igor (WaveMetrics) and Axograph 
scientific. The peak net inward current (reflecting the difference between the inward INa and the other 
voltage-dependent outward currents) was quantified after subtracting the capacitive current, and 
assumed ohmic leak current was scaled from the response to hyperpolarizing pulses (Clarke et al 
2012). Voltage responses to current injection were recorded from the cell’s resting potential 
(applying 25 pA steps for 200 ms from – 100 to 500pA). Post-recording, the patch electrode was 
removed from the neuron, which was later identified by the detection of neurobiotin.  
4.2.5 Immunocytochemistry of cortical cultures 
Neuronal cultures were fixed with 4% PFA for 30min at room temperature and washed in 0.01M 
PBS three times for ten minutes. Fixed cultures were then blocked for non-specific binding (0.3% 
Triton X-100 in 0.01M PBS with 10% normal bovine serum) for 1hr at room temperature and 
incubated in primary antibody combinations in diluent (0.01M PBS with 5% normal bovine serum) 
at 4oC overnight. Specimens were then washed a further three times for ten minutes and incubated in 
appropriate secondary antibodies (Alexa Fluor anti-rat 488, anti-rabbit 647, anti-mouse 647) diluted 
in PBS (1:1000, Molecular Probes) for 90 minutes at room temperature. DAPI (1:10000 dilution, 
5mg/ml stock) was added for the final ten minutes to visualise nuclei. Specimens were then 
thoroughly washed with PBS and mounted with Permafleur media (DAKO) onto slides. 
Cultures were probed for Gad67-GFP expression (enhanced by rat anti-GFP, 1:3000, Nacalai tesque) 
along with interneuronal markers (rabbit anti-CB, 1:2000, Millipore; rabbit anti-CR, 1:2000, Swant; 
mouse anti-PV, 1:2000, Swant; rabbit anti-NPY, 1:2000, Abcam; rabbit anti-SOM, 1:1500, 
Immunostar; rabbit anti-VIP, 1:2000, Immunostar), synaptic markers (rabbit anti-synaptophysin, 
1:1000, Millipore; mouse PSD-95, 1:500, Abcam) and vesicular transporters (rabbit anti-VGAT, 
1:500, Synaptic Systems; mouse anti-VGLUT-1, 1:500, Synaptic Systems).  
Visualization of neurobiotin-filled patched cells was achieved by incubation of specimens with 
fluorescently conjugated Alexa Fluor® streptavidin-546 (Molecular ProbesTM; 0.1% Triton X-100), 
prior to incubation with primary antibodies. This approach was used to identify patched neurons for 
post-hoc morphological analyses. 
4.2.6 Confocal microscopy of cortical cultures 
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Neurons were visualized using a spinning disk laser confocal (UltraView®VOX, Perkin Elmer) on 
an inverted microscope (Nikon TiE, Nikon) equipped with a 20x (Plan-Apo 0.75), 40x (Plan-Apo 
0.95) and 60x (Plan-Apo 1.2) objective lenses. Images were acquired using an Orca R2 camera 
(C106000, Orca, Hamamatsu) and analysed using imaging capture software (Velocity v6 3.0, 2013, 
Perkin Elmer). Z-stack images of interneuronal populations were captured with a 20x objective 
(10µm, 1µm intervals), neurobiotin-filled interneurons on a 40x objective (5µm, 0.5µm intervals) 
and synaptic markers with a 60x objective (5µm, 0.5µm intervals).  
4.2.7 Image analysis and cell tracing  
Interneuron subtype proportions represented by Gad67-GFP interneurons were determined in Image 
J (NIH) by quantifying the relative expression of interneuron marker fluorescence co-localised with 
Gad67-GFP expression, and presenting data relative to total GFP expression [arbitrary units (AU)]. 
For morphological analyses, reconstruction of the streptavidin-positive processes of patch clamped 
interneurons was completed with tracing of cells through Z-stack series using the cell tracing 
software NeurolucidaTM (MBF Bioscience, USA). Each interneuron, that met the inclusion criteria 
for electrophysiological assessment (access resistance < 15 MΩ), was evaluated with NeurolucidaTM 
Explorer II to determine the total branch orders, numbers and length (MBF Bioscience, USA). The 
complexity of the neurite arbors was also assessed by performing a Sholl analysis with concentric 
circles placed at 10µm intervals radiating outward from the cell body.  
4.2.8 Statistical analysis 
To determine the effect of SOD1G93A mutation on cortical interneuron maturation, developmental 
and functional data was statistically analysed using GraphPad Prism (Version 5.0, La Jolla, CA). For 
all electrophysiological assessments, data from Gad67-GFP cortical interneuron populations was 
pooled based on morphological features and two interneuron groups considered:  bipolar 
interneurons with two-neurobiotin filled processes on opposite poles of the cell soma, and multipolar 
interneurons with at least three processes originating from the cell soma (Cauli et al 2014). For all 
electrophysiological statistical comparisons unpaired Student’s t tests were performed, with the 
exception of frequency and amplitude assessments, which was evaluated with paired Student’s t 
tests. Unpaired Student’s t tests were also used to determine differences between the compositions of 
interneuron cultures and to evaluate the morphology of whole-cell patch clamped interneurons, with 
the exception of cumulative frequency distribution plots, which were assessed with the Kolmogorov-
Smirnov test to compare cumulative distributions. To examine relationships between neuronal 
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morphology and electrophysiological parameters, a non-parametric Pearson’s r2 was reported. P < 
0.05 was considered statistically significant. Data is expressed as means ± standard error of mean. 
Unless otherwise stated, a minimum of three separate cultures was used for each experiment, with 3 
technical replicates per culture (n = 3).  
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4.3 RESULTS  
4.3.1 Characterisation of Gad67-GFP interneurons in vitro  
To determine the effect of the SOD1G93A mutation on cortical interneurons, cortical cultures derived 
from E15.5 Gad67-GFP::SOD1G93A and Gad67-GFP::C57Bl6 (WT) transgenic mice were initially 
characterised for key interneuronal and synaptic markers. Utilising immunocytochemistry, the 
current investigation identified that growing and developing interneurons with the SOD1 mutation 
showed no significant changes in expression and localization of synaptic proteins compared to WT 
interneurons (Figure 4.1). Cortical interneurons followed a distinct pattern of development, with the 
pre-synaptic protein synaptophysin and post-synaptic density 95 (PSD-95) transitioning from a 
diffuse pattern of expression at 3-7 DIV to become punctate and extended along elaborate neurite 
processes at 10-14 DIV (Figure 4.1 a-d). The maturation of interneuron populations was also 
examined by expression of the vesicular glutamate transporter (VGLUT-1) and the vesicular GABA 
transporter (VGAT) with Gad67-GFP soma and processes across the 3-14 DIV time course (Figure 
4.1 e-h), there was no overt differences observed between the co-localisation and expression of these 
vascular proteins in SOD1G93A and WT populations. At 3-7 DIV, Gad67-GFP-positive interneuron 
soma and processes had distinct and robust co-localised VGLUT-1 expression (appearing white in 
images) that was markedly reduced by 10-14 DIV. In comparison, co-localisation of VGAT with 
GFP (yellow in images) at 3-7 DIV was diffuse and non-specific, but by 10-14 DIV had become 
distinctly punctate along GFP-positive cell soma and processes. This suggests that SOD1G93A Gad67-
GFP cortical interneurons undergo a similar pattern of maturation to WT populations.  
To examine if the migration of interneurons was affected by the SOD1G93A mutation, the 
composition of WT and SOD1G93A cortical cultures was characterised to determine if the proportion 
of different inhibitory types represented by Gad67-GFP cortical interneurons was altered in 
SOD1G93A cortical cultures, and by association, the migration of interneurons to the cortex from the 
ganglionic eminence. Immunocytochemistry revealed a diverse range of interneuron populations 
present in both the Gad67-GFP::SOD1G93A and Gad67-GFP::C57Bl6 (WT) cultures at 10 DIV 
(Figure 4.2). Labelling of the calcium-binding proteins CB, CR and PV showed clear and distinct 
cortical interneurons co-localised with GFP expression (Figure 4.2 a-c). Similarly, labelling of the 
neuropeptides, NPY, SOM and VIP identified heterogeneous interneuron populations co-localised 
with GFP that had a range of different morphologies (Figure 4.2 d-f). Assessing the extent of co-
localised interneuronal and GFP fluorescence, relative to total GFP express (AU), showed no 
significant change in the proportion of populations represented by Gad67-GFP expression in WT and 
  
 
 
 
 
 
 
 
Figure 4.1. Development of Gad67-GFP interneurons in vitro. 
To examine neuronal maturity, dissociated Gad67-GFP interneurons were grown as a 
monolayer on a poly-L-lysine substrate and synaptic labelling performed at 3 DIV, 7 
DIV, 10 DIV and 14 DIV. a-b, At 3-7 DIV triple labelling for GFP (green), the pre-
synaptic maker synaptophysin (Syn, red) and post-synaptic density protein 95 (PSD-95, 
cyan) was diffuse in WT (a i, b i) and SOD1G93A (a ii, b ii) interneurons. c-d, At 10-14 
DIV immunoreactivity for synaptophysin and PSD-95 was punctate and co-localised 
with GFP-positive processes and cell soma in WT (c i, d i) and SOD1G93A (c ii, d ii) 
interneurons. e-h, Labelling of the vesicular transporters for GABA (VGAT, red) and 
glutamate (VGLUT-1, cyan). e-f, At 3-7 DIV VGAT labelling was diffuse and 
VGLUT-1 was co-localised with GFP at illustrated by arrows (white in images). g-h, 
At 10-14 DIV VGAT labelling is punctate and co-localised with GFP processes as 
illustrated by arrows (yellow in images), while VGLUT-1 is not co-localised with GFP 
processes. Scale bar in (a-h) 20µm. 
 
 
 
  

  
 
 
 
 
 
 
 
 
 
Figure 4.2. Characterisation of Gad67-GFP interneurons in vitro. 
To determine the characteristics of Gad67-GFP+ interneurons in vitro, primary cortical 
cultures were derived from E15.5 embryos and grown as a monolayer on a poly-L-
lysine substrate in order to label interneuron populations at 10 DIV. a-c, Cells were 
labelled for the calcium-binding proteins, calbindin (CB, a), calretinin (CR, b) and 
parvalbumin (PV, c), and the neuropeptides, neuropeptide Y (NPY, d), somatostatin 
(SOM, e) and vasoactive intestinal peptide (VIP, f) in Gad67::WT (i) and 
Gad67::SOD1G93A (ii) cortical cultures. Double labelling of interneuronal markers with 
Gad67-GFP identified key inhibitory cortical interneuron populations co-localised with 
GFP, as shown in inserts. g, Analysis of the relative expression of interneuron marker 
fluorescence co-localised with Gad67-GFP expression, relative to total GFP expression, 
revealed no significant difference in the proportion of interneuron subtypes represented 
by Gad67-GFP interneurons in WT and SOD1G93A cultures (P < 0.05, unpaired 
Student’s t test). Scale bar in (a-f) 20µm. 
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SOD1G93A cultures (P > 0.05, unpaired Student’s t test) (Figure 4.2 g). These data indicate that the 
SOD1G93A mutation might not initially affect the proportion of Gad67-GFP cortical interneurons in 
vitro.  
4.3.2 The SOD1 mutation affects the electrophysiological profile of Gad67-GFP interneurons  
Having established that a similar proportion of interneuron subtypes was represented by Gad67-GFP 
interneuron populations in SOD1G93A and WT cultures, the next aim was to determine whether 
Gad67-GFP interneurons had altered intrinsic electrophysiological properties at this early stage of 
development, as has been demonstrated in motor neurons that express the SOD1G93A mutation (Pieri 
et al 2003). Whole-cell patch clamp recordings were made from GFP-positive interneurons that were 
10 DIV, which were concurrently filled with neurobiotin for post-hoc identification with 
streptavidin-546 labelling. As interneurons have incredibly varied electrophysiological properties 
(Markram et al 2004), for these analyses cortical interneurons were separated into two subclasses 
based on their neurite morphology (Cauli et al 2014): bipolar interneurons were considered GFP-
positive interneurons with two neurobiotin filled processes originating from opposite sides of the cell 
soma (Figure 4.3 a-d) and multipolar interneurons, Gad67-GFP-positive cells with at least three 
neurobiotin filled processes originating from the cell body (Figure 4.4 a-d).  
The electrophysiological profile of bipolar interneurons was first investigated and it was determined 
that WT populations at 10 DIV had a mean resting membrane potential (RMP) of ~ -60 mV (Figure 
4.3 e), a capacitance of ~24 pF (Figure 4.3 f), an input resistance of ~610 MΩ (Figure 4.3 g), and a 
peak inward current at 0 mV of ~ -1.6 nA (Figure 4.3 h). Passive membrane properties are 
consistent with in vivo parameters of P8 E15.5-born CGE-derived cortical interneurons, although the 
capacitance appears lower (Karayannis et al 2012). The average threshold to excite WT bipolar 
interneurons was found to be ~ -42 mV (Figure 4.3 j), the average frequency of action potentials ~8 
Hz (Figure 4.3 k) and the minimal strength of stimulus that can excite the cells (rheobase) ~210 pA 
(Figure 4.3 l). In the SOD1G93A Gad67-GFP bipolar interneurons the previously mentioned 
parameters were unchanged compared to controls, including: RMP, capacitance, input resistance, 
peak inward current, threshold, frequency and rheobase (P > 0.05, unpaired Student’s t test). 
However the peak outward current was significantly increased in SOD1G93A interneurons (~1.4 ± 
0.13 nA) compared to WT populations (~0.8 ± 0.07 nA, P < 0.05, unpaired Student’s t test) (Figure 
4.3 i). Additionally, the action potential waveform duration was significantly increased in SOD1G93A 
interneurons (~10.48 ± 0.69 ms) compared with WT bipolar interneurons (~4.72 ± 0.99 ms, P < 0.05, 
unpaired Student’s t test) (Figure 4.3 m). To analyse intrinsic excitability, frequency-current (f-I) 
  
 
 
  
 
 
 
Figure 4.3. The SOD1G93A mutation affects the peak outward current and intrinsic 
excitability of bipolar Gad67-GFP interneurons at 10 DIV.  
To investigate the innate electrophysiological properties of bipolar interneurons, data of 
whole-cell patched clamped interneurons with two neurobiotin-positive processes 
visible was pooled. a, Phase image of whole-cell patch clamped bipolar interneurons 
(a) from Gad67::WT (a i) and Gad67::SOD1G93A (a ii) primary cultures. b-d, Patched 
interneurons were GFP-positive (b), with neurobiotin-filled interneurons labelled by 
streptavidin-546 (c) used to post-hoc identify bipolar morphology based on co-localised 
labelling with GFP (d). Graphs show the average electrophysiological data for WT and 
SOD1G93A cultures at 10 DIV, with individually patched interneurons represented as 
data points. e-m, Intrinsic parameters of bipolar SOD1G93A interneurons showed no 
change relative to controls in resting membrane potential (RMP, e) capacitance (f), 
input resistance (g), peak inward current (h), threshold (j), frequency (k) or rheobase 
(l), while peak outward current was significantly increased in SOD1G93A interneurons 
(i), as was the duration of action potential waveform (m) (*P < 0.05, unpaired 
Student’s t test) n, The average frequency of action potentials plotted against injected 
current show that the intrinsic excitability of bipolar SOD1G93A interneurons is 
significantly decreased compared with WT populations (*P < 0.05, paired Student’s t 
test). Scale bar in (a-d) 20µm. 
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relationships were generated from responses to a series of depolarising current steps (100 to 500pA, 
in 25 pA increments, 200 ms duration). Comparisons were performed on data pooled from 
recordings of bipolar cells and it was found that SOD1G93A interneurons fired at significantly lower 
rates than WT interneurons (P < 0.05, paired Student’s t test) (Figure 4.3 m). This suggests that at 
this early developmental stage the SOD1G93A mutation may alter the intrinsic excitability and 
intrinsic properties of bipolar interneurons.  
To assess whether this altered electrophysiological profile was unique to bipolar interneurons, 
multipolar interneurons were next examined. Similar to bipolar interneurons, the RMP, capacitance, 
input resistance, peak inward current, threshold, frequency and rheobase were unaltered in Gad67-
GFP-positive SOD1G93A multipolar interneurons compared to Gad67-GFP-positive WT multipolar 
interneurons (P > 0.05, unpaired Student’s t test) (Figure 4.4). At 10 DIV the WT multipolar 
interneurons had a RMP of ~ -68 mV (Figure 4.4 e), a capacitance of ~32 pF (Figure 4.4 f), an input 
resistance of ~520 MΩ (Figure 4.4 g), and a peak inward current at 0 mV of ~ -1.9 nA (Figure 4.4 
h). The average threshold to excite WT bipolar interneurons was found to be ~ -36 mV (Figure 4.4 
j), the average frequency of action potentials ~6 Hz (Figure 4.3 k), rheobase ~171 pA (Figure 4.3 l) 
and action potential duration ~6 ms (Figure 4.3 m). However, SOD1G93A derived multipolar 
interneurons had contrasting alterations in peak outward current and action potential waveform 
compared to bipolar populations. While the action potential waveform duration was unaltered 
compared to WT multipolar populations, the peak outward current in SOD1G93A multipolar 
interneurons was decreased (SOD1G93A, ~1.1 ± 0.2 nA; WT, ~2.0 ± 0.2 nA, P < 0.05), in direct 
contrast to the magnitude of response observed in SOD1G93A bipolar interneurons (Figure 4.4 i). 
Assessment of intrinsic excitability showed that SOD1G93A multipolar interneurons also fired at 
significantly lower rates compared with WT populations (P < 0.05, paired Student’s t test) (Figure 
4.4 n). This indicates that there are differential responses of bipolar and multipolar interneurons to 
the expression of the SOD1G93A mutation, however the intrinsic excitability of these populations 
appears to be similarly affected. 
4.3.3 The SOD1 mutation affects the morphological development of Gad67-GFP interneurons  
During development the maturation of cortical interneuron processes has been shown to be an 
activity-dependent process, with perturbed excitability shown to differentially influence the neurite 
path length of discrete interneuron populations (De Marco Garcia et al 2011, Le Magueresse & 
Monyer 2013). As the intrinsic excitability of interneurons was altered, and the peak outward current 
was differentially altered, the next aim of this study was to determine whether the presence of the 
  
 
 
 
 
 
Figure 4.4. The SOD1G93A mutation affects the peak outward current and intrinsic 
excitability of multipolar Gad67-GFP interneurons at 10 DIV.  
To investigate the innate electrophysiological properties of multipolar interneurons, 
data of whole-cell patched clamped interneurons with more than two neurobiotin-
positive processes visible was pooled. a, Phase image of whole-cell patch clamped 
multipolar interneurons (a) from Gad67::WT (a i) and Gad67::SOD1G93A (a ii) primary 
cultures. b-d, Patched interneurons were GFP-positive (b), with neurobiotin-filled 
interneurons labelled by streptavidin-546 (c) used to post-hoc identify multipolar 
morphology based on co-localised labelling with GFP (d). Graphs show the average 
electrophysiological data for WT and SOD1G93A cultures at 10 DIV, with individually 
patched interneurons represented as data points. e-m, Intrinsic parameters of multipolar 
SOD1G93A interneurons showed no change relative to controls in resting membrane 
potential (RMP, e) capacitance (f), input resistance (g), peak inward current (h), 
threshold (j), frequency (k) rheobase (l), or action potential waveform duration, (m) 
while peak outward current was significantly decreased  in SOD1G93A interneurons (i) 
(*P < 0.05, unpaired Student’s t test). n, The frequency of action potentials evoked for 
a range of current injections show that the intrinsic excitability of multipolar SOD1G93A 
interneurons is significantly decreased compared with WT populations (*P < 0.05, 
paired Student’s t test). Scale bar in (a-d) 20µm.  
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SOD1 mutation altered the development of interneuron morphology in vitro. To examine interneuron 
morphology, neurobiotin filled whole-cell patch clamped Gad67-GFP interneurons were post-hoc 
labelled with streptavidin-546 and reconstructed to assess neurite complexity. Morphological 
assessment was divided into bipolar and multipolar interneuron populations. The initial examination 
of bipolar interneurons identified cells with well-developed neurite trees  (Figure 4.5 a), which 
morphologically resembled previous descriptions of cortical bipolar interneurons (Freund & Buzsaki 
1996) and appeared similar to SOD1G93A populations (Figure 4.5 b). This was confirmed by the 
assessment of neurite complexity by Sholl analysis (P > 0.05, unpaired Student’s t test) (Figure 4.5 
c), and the additional examination of branch order, total neurite tree path length and total branch 
numbers (P > 0.05, unpaired Student’s t test) (Figure 4.5 d-f), which were also unaltered in 
cumulative frequency distribution plots of SOD1G93A bipolar interneurons compared with WT 
populations (P > 0.05, Kolmogorov-Smirnov test, n = 16 interneurons analysed across n = 5 cultures 
per genotype) (Figure 4.5 g-i).  
In contrast, assessment of the multipolar SOD1G93A interneurons revealed a larger and more complex 
neurite tree (Figure 4.6 a) compared with multipolar WT interneurons (Figure 4.6 b). By 
performing a sholl analysis it was determined that SOD1G93A most significantly affected branching in 
the intermediate zone of the multipolar interneuron neurite arbor, ~100-250µm from cell soma (P < 
0.05, unpaired Student’s t test) (Figure 4.6 c). By examining branch orders on neurite trees it was 
confirmed that multipolar SOD1G93A interneurons had increased complexity compared with WT 
multipolar interneurons (SOD1G93A, 15 ± 1.6; WT, 11 ± 0.7, P < 0.05) (Figure 4.6 d). This was 
emphasised by a significant increase in total neurite tree path length (SOD1G93A, 2467 ± 264µm; WT, 
3801 ± 506µm, P < 0.05) (Figure 4.6 e) and total branch number of multipolar interneurons 
(SOD1G93A, 135 ± 13; WT, 98 ± 10, P < 0.05) (unpaired Student’s t test) (Figure 4.6 f). The right-
shifted cumulative frequency plots, showing that SOD1G93A multipolar interneurons have more 
neurite branches, a longer neurite path length and total branch numbers relative to WT multipolar 
interneurons, further highlighting this phenotype (P < 0.05, Kolmogorov-Smirnov test, n = 31 
interneurons analysed across n = 6 cultures per genotype) (Figures 4.6 g-i). These date indicate that 
although the intrinsic electrophysiological profiles of both bipolar and multipolar interneurons are 
altered, multipolar interneuron populations may be more susceptible during morphological 
development. Of note, a correlation analysis found that multipolar interneuron morphology was not 
correlated with firing frequency of these cells relative to total branch number (SOD1G93A, R2 0.01, P 
> 0.72) and length (SOD1G93A, R2 0.05, P > 0.51), nor was branch number (SOD1G93A, R2 0.02, P > 
0.66) and length (SOD1G93A, R2 0.06, P > 0.43) correlated to their peak outward current.  
  
 
 
 
 
 
 
 
Figure 4.5. The SOD1G93A mutation does not affect the morphological 
development of Gad67-GFP bipolar interneurons at 10 DIV. 
In order to assess the morphology of bipolar interneurons in vitro, patch-clamped 
Gad67-GFP interneurons were post-hoc labelled for neurobiotin to visualise processes. 
a-b, Bipolar interneurons (with only two processes extending from the cell soma) 
positive for GAD67-GFP and neurobiotin were identified and reconstructed from 
Gad67::WT (a) and Gad67::SOD1G93A (b) primary cultures. Each concentric circle 
represents 10µm, and each dashed line represents 50µm, from the cell soma. (c-f), 
Traced interneurons show that neurite complexity by Sholl analysis (c), magnitude of 
branching order (d), total neurite tree path length (e), and total branch number (f) were 
unaltered in bipolar SOD1G93A interneurons compared with WT interneurons (P > 0.05, 
unpaired Student’s t test). g-i, The similarity of SOD1G93A bipolar interneurons with 
WT populations is emphasised by overlap of measures in cumulative frequency 
distribution plots (P > 0.05, Kolmogorov-Smirnov test to compare cumulative 
distributions).  
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Figure 4.6. The SOD1G93A mutation affects the morphological development of 
Gad67-GFP multipolar interneurons at 10 DIV. 
a-b, To assess the morphology of multipolar interneurons in vitro, patch-clamped 
Gad67-GFP interneurons (with more than two processes extending from the cell soma) 
positive for neurobiotin were identified and reconstructed from Gad67::WT (a) and 
Gad67::SOD1G93A (b) primary cultures. Each concentric circle represents 10µm, and 
each dashed line represents 50µm, from the cell soma. a-c, In traced neurons (a-b) the 
bolded dashed lines represent the 100-250µm zone from the cell soma in which 
SOD1G93A multipolar interneurons have significantly increased neurite complexity 
compared to WT populations (c) as demonstrated by Sholl analysis (*P < 0.05, 
unpaired Student’s t test). d-f, Graphs show the magnitude of branching order (d), total 
neurite tree path length (e), and total branch number (f) was significantly increased in 
multipolar SOD1G93A interneurons compared with WT populations (*P < 0.05, 
unpaired Student’s t test). g-i, A greater percentage of multipolar SOD1G93A 
interneurons had higher order processes (g), a longer total neurite path length (h), and 
an increased total branch number (i) as emphasised by the right shift in the cumulative 
frequency distribution plots compared to WT distributions (*P < 0.05, Kolmogorov-
Smirnov test to compare cumulative distributions).  
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4.4 DISCUSSION  
ALS is a non-cell autonomous neurodegenerative disease in which pathogenic processes initiated 
during early post-natal development may insidiously prime networks to fail later in life. The previous 
findings form this thesis support the early and continual involvement of specific interneuron 
populations throughout the disease course of the SOD1G93A mouse. In addition, the recapitulation of 
findings in the ALS motor cortex has suggested that cortical interneuronal involvement may be 
related to pathology and potentially to pathophysiology in this key disease-affected region. However, 
several aspects of the role of cortical interneurons in disease remain unclear, including whether they 
are inherently vulnerable in the ALS network, potentially due to alterations in network excitability, 
or whether they may be innately susceptible to the expression of ALS mutations, such as the 
SOD1G93A mutation, at the cellular level. The current chapter investigated the effect of the SOD1G93A 
mutation on cortical interneuron maturation, morphological development and intrinsic function in 
vitro, in order to firstly ascertain if cortical interneurons are altered during development and 
secondly, to determine the validity of intrinsic or activity-driven alterations.  
4.4.1 Cortical interneurons are susceptible to SOD1G93A during development  
In this chapter, electrophysiological and morphological data provide considerable evidence for 
abnormal cortical interneuron development, which includes the alteration of neurite morphology and 
intrinsic firing properties; parameters that are also altered in motor neurons with the SOD1G93A 
mutation. It is demonstrated that cortical interneurons develop appropriate passive membrane 
properties in both control and SOD1G93A cortical interneurons, including membrane capacitance, 
input resistance and resting membrane potential. However, it is revealed that reduced spontaneous 
intrinsic activity and altered peak outward current occur in SOD1G93A derived cortical interneurons. 
Additionally, there appears to be a differential involvement of the peak outward current and action 
potential waveform in bipolar and multipolar populations. The action potential waveform was slower 
in SOD1G93A bipolar interneurons compared with WT equivalents, while it was unaltered in 
SOD1G93A multipolar interneurons. The peak outward current was decreased in SOD1G93A multipolar 
interneurons and increased in SOD1G93A bipolar interneurons, while in both cell populations an 
intrinsic reduction in excitability appears to be a consistent feature. This novel data indicates that 
early interneuron dysfunction may arise from altered biophysical properties that differentially 
influence the peak outward current and the action potential waveform in bipolar and multipolar 
cortical interneurons, which may contribute to the initiation of downstream degenerative pathways 
that predate their role in cortical circuits later in life.  
   70  
 
4.4.2 A role for potassium channels? 
Previous studies in animal models and in FALS patients have focused on persistent sodium currents 
as a mechanism of motor neuron hyperexcitability (Kuo et al 2005, Pieri et al 2009, Vucic & Kiernan 
2010), however, more recently studies in patient-derived motor neurons have suggested the 
additional importance of voltage-activated potassium channels (Wainger et al 2014, Devlin et al 
2015). Devlin and colleagues used modelling to predict that the mode of alteration of motor neurons 
derived from patients with TARDBP and C9orf72 mutations was likely reflected by perturbation of 
sodium and potassium currents (Devlin et al 2015). While they speculate that a general switch from 
hyperexcitability to hypoexcitability may result from a loss of ion channels in these cells, Wainger 
and colleagues demonstrate that patient-derived motor neurons with a SOD1 mutation have no 
difference in sodium current peak amplitudes, but instead a reduction in delayed-rectifier current 
magnitude attributed to decreased function of voltage-activated potassium channels (Wainger et al 
2014). Administration of the Kv7 channel activator retigabine was found to reverse hyperexcitability 
observed in this model. In line with a more generalised mechanism of potassium channels 
involvement in the disease, hyper-methylation and down-regulation of potassium channel genes has 
also been observed in epigenetic studies of sporadic ALS (Figueroa-Romero et al 2012). While the 
pathways connecting disease-causing mutations with altered ion channels remain to be elucidated, 
the epigenetic suppression of potassium channels may indicate a convergent susceptibility in the 
disease, which may be instigated by accumulation of environmental stressors throughout a person’s 
life, or at birth, through inherited mutation.  
Of relevance to this study, a previous publication has described a subtype-specific response of 
interneurons to the expression of the Kir2.1 inward-rectifier potassium ion channel (Karayannis et al 
2012). In this study, Kir2.1 expression in interneurons derived from the caudal ganglionic eminence 
induced intrinsic hypoexcitability, leading to a marked developmental change in intrinsic 
electrophysiological properties, specifically, a slower duration of the action potential waveform. In 
addition, there was a distinct lack of intrinsic or activity-dependent compensation for these 
alterations. This may be relevant to the findings of this study, as the majority of interneurons derived 
from the caudal ganglionic eminence are bipolar interneurons (Fogarty et al 2007), and the 
predominant response of these cells to SOD1G93A expression in this study was through altered 
intrinsic electrophysiological properties, namely altered peak outward current, intrinsic 
hypoexcitability and the bipolar-specific slowing of the action potential waveform. Therefore, as 
there is a precedent for perturbation of potassium channels in both sporadic and familial ALS 
(Wainger et al 2014), it may be likely that the alteration of bipolar cortical interneurons is also 
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initiated by aberrant function of potassium channels. However, such a model does not explain the 
alterations observed in the multipolar populations.  
In multipolar interneurons hypoexcitability was identified similar to bipolar interneurons, but the 
action potential waveform was unaltered and an inverse response to the peak outward current was 
demonstrated in addition to the presence of a more elaborate neurite tree. A number of factors may 
contribute to the different responses observed in bipolar and multipolar interneurons, including the 
distinctly different embryonic origins of bipolar and multipolar interneuron subtypes. As bipolar 
interneurons arise from the caudal ganglionic eminence and multipolar interneurons are 
predominately generated within the medial ganglionic eminence (Fogarty et al 2007, Miyoshi et al 
2007, Colasante & Sessa 2010), by a developmental classification system they are considered 
distinctly different interneuron classes. Moreover, interneurons generated within these areas are 
conferred distinct ion channel properties, morphology and immunohistochemical profiles that 
delineate further distinct classification of interneuron subtypes (Wonders & Anderson 2006). 
Therefore, distinct ion channels present on bipolar and multipolar interneuron subtypes could 
determine their response, and innate vulnerability to the SOD1G93A mutation, particularly if the 
SOD1G93A mutation interacts with specific subsets of ion channels, as has been indicated by previous 
research (Kuo et al 2005, van Zundert et al 2008).  
A SOD1-dependent pathogenic mechanism targeting specific ion channels on interneurons could 
explain the different responses in peak outward current and action potential waveform, as these 
measures of neuronal activity are both highly influenced by ion channel composition and kinetics 
(McBain & Fisahn 2001). Therefore, it would be interesting to employ pharmacological approaches 
to further explore specific ion channels involved in the peak outward current and action waveform 
duration. This may provide further insight into SOD1-dependent mechanisms, and allow for better 
comparison of ALS literature about early modification of circuitry in the developing ALS cortex.  
4.4.3 The morphology of select cortical interneuron populations is affected during 
development in the presence of the SOD1G93A mutation 
While this study suggests an importance of the intrinsic biophysical properties of cortical 
interneurons in relation to development of normal function, altered morphological development may 
also be an important feature of the innate interneuron response to the presence of the SOD1G93A 
mutation. Post-hoc labelling of whole-cell patch clamped interneurons demonstrated a distinct 
difference between the presence and absence of a morphological phenotype in multipolar and bipolar 
interneuron subtypes, respectively. While there is limited understanding of the key factors required 
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for normal maturation of interneuron morphology throughout development (Le Magueresse & 
Monyer 2013), it is increasingly recognised that the maturation of GABAergic neurotransmission is a 
protracted process that takes place in discrete steps and results from a dynamic interaction between 
developmentally directed gene expression and brain activity (Ben-Ari 2002). The differentiation of 
interneuronal subtypes is primarily attributed to this first process, and is largely defined prior to 
migration out of the ganglionic eminence (Wonders & Anderson 2006, Le Magueresse & Monyer 
2013). However, a study by De Marco Garcia and colleagues has demonstrated that the migration 
and development of particularly neurite arbor length may be an activity-dependent process that 
differentially affects discrete interneuron populations (De Marco Garcia et al 2011). Therefore, in the 
context of the increased neurite arbor demonstrated in multipolar SOD1G93A derived interneurons, 
this may reflect a change in the innervation field of these cells secondary to altered excitability in the 
cortical culture.  
It remains to be determined what may initially drive any altered excitability in the presence of the 
SOD1G93A mutation, whether this is caused by interneurons directly, or quite possibly by an initial 
alteration of excitatory pyramidal neurons in the culture. However, it appears that the alteration in 
morphology of multipolar SOD1G93A interneurons is not directly correlated with the altered firing 
frequency or peak outward current of these cells. It is widely documented that hyperexcitability does 
exist in the SOD1G93A model at developmental stages (Kuo et al 2004, Pieri et al 2009). If excitatory 
neurons do initiate alterations in excitability it could be possible that they may contribute to the 
development of altered intrinsic excitability of interneurons (Pieri et al 2009). However, as it is 
poorly understood to what extent the intrinsic firing properties of interneurons are determined by 
activity during development, or are pre-determined by a genetic trajectory (Le Magueresse & 
Monyer 2013), further investigations will be required to establish if interneuron deficits develop 
independent of pyramidal neurons with the SOD1G93A mutation. Nonetheless, this data indicates that 
bipolar and multipolar interneurons have innately different responses to the presence of the 
SOD1G93A mutation. Whether this is mediated by altered network activity through excitatory neurons 
or by distinct ion channel compositions in a cell autonomous manner remains to be determined.  
4.4.4 The maturation and composition of cortical cultures interneurons was similar in WT 
and SOD1G93A derived cultures.  
Another possibility that requires further investigation is the notion that differences in the morphology 
of cortical interneuron populations might be caused by developmental acceleration of populations 
from distinct sub-regions of the ganglionic eminence. In vitro studies have suggested that alterations 
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in motor neuron populations may be due to an accelerated pace of maturation (van Zundert et al 
2008, Quinlan et al 2011), however this was indicated by a decreased capacitance of motor neurons 
relative to controls, which was not observed in this study. Moreover, the synaptic and vesicular 
development of populations appeared unaltered in cultures, as evidenced by a similar pattern of 
somatic and neurotic labelling over the time course. The pattern of synaptophysin and PSD-95 
labeling is consistent with normal developmental maturation of cultures (Thiel 1993, Nikonenko et al 
2008) and the pattern of punctate VGAT labeling is consistent with inhibitory cell maturation 
(Chaudhry et al 1998). Therefore, the rate of in vitro development is observed to be seemingly 
normal, although as this later observation is not quantitative, cell sorting and quantitative expression 
studies may improve the strength of these interpretations.  
Nonetheless, as previously mentioned, the development of interneuron networks can also be 
modified by altered migration in response to perturbed excitability at critical stages of development 
(De Marco Garcia et al 2011). Several genetic fate-mapping studies have shown that the pre-cursors 
of distinct cortical interneuron subtypes are generated within different regions of the ganglionic 
eminence [see review (Wonders & Anderson 2006)]. Pre-cursors of cortical interneurons expressing 
CB, PV, SOM, as well as multipolar CR interneurons, are generated exclusively from the medial 
ganglionic eminence, while precursors of all bipolar CR-expressing interneurons, and most NPY-
expressing interneurons are generated in lateral/caudal ganglionic eminences (Fogarty et al 2007, 
Miyoshi et al 2010, Miyoshi & Fishell 2011). Therefore, if the mutation affected either the 
development or migration of interneuron subtypes from distinct regions of the ganglionic eminence, 
then it may bias the subtypes present in the cortex and those assessed in the E15.5 embryonic cortical 
cultures. As an index of potential migratory deficits, the proportion of subtypes represented by 
Gad67-GFP interneurons was assessed in cortical cultures, and it was found that there was no overt 
difference in the proportion of Gad67-GFP interneuron subtypes. Although, this result may be 
treated with some caution, as a better measure of interneuron migratory deficits is the use of genetic 
fete mapping studies. An additional consideration is that, although some Gad67-GFP interneurons 
are present in the neocortex by E15.5, when cortical tissue was dissociated for culture, not all have 
migrated from the ganglionic eminence at E15.5, nor are all interneurons in the culture labelled by 
GFP (Tamamaki et al 2003). As such, conclusions are limited to the proportion of Gad67-GFP 
interneurons that are present in the Gad67-GFP neocortex at E15.5, which are cultured, and to those 
that are labelled by GFP. In this respect, it is important to note that the Gad67-GFP population 
typically increases in number between 4 and 9 DIV, due to cell proliferation, and this population 
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reach a maximum size by 9-11 DIV (Southwell et al 2012). Therefore, a good representative 
population of Gad67-GFP interneurons is present in vitro at 10 DIV.  
Irrespective of the need to further define the exact developmental stage when interneuron 
development may first become altered and the need to explore potential cortical migration deficits, it 
appears that there is considerable evidence for altered cortical interneuron development in the 
presence of the SOD1G93A mutation. Why this remains subclinical for such a long period, remains to 
be determined, however, possible explanations include the incredible capacity for inhibitory circuitry 
to compensate for alterations in networks through homeostatic regulatory mechanisms (Karayannis 
et al 2012). In the context of these current findings, it may be posited that divergent responses of 
bipolar and multipolar interneurons, represent a priming bipolar population, and a compensatory 
multipolar population that masks the effects of network dysfunction until it becomes critically 
saturated later in life. It will be of interest for future studies to examine how these populations 
functionally integrate in the ALS cortical network, particularly as there is potential for perturbation 
of these populations through sporadic epigenetic, and familial inherited, disease pathways.   
4.4.5 Conclusion  
In summary, these results indicate for the first time that distinct intrinsic biophysical properties and 
intrinsic firing properties of cortical interneuron populations may be innately susceptible to ALS 
mutations. In comparison, a distinction is made between a morphological phenotype in bipolar and 
multipolar cortical interneuron populations, which may highlight the unique vulnerability or 
contribution of these populations in the excitable ALS network. Additionally, this study 
demonstrates the sensitive nature of electrophysiological studies of interneuron populations, and 
highlights the potential importance of subtype-specific interneuronal studies to delineate the true 
complexity and contribution of these populations in the disease setting. Furthermore, in the context 
of the previous findings in this thesis, demonstrated immunohistochemical alteration of distinct 
populations in Chapter 2, it is suggested that further studies should be conducted to resolve the 
contribution of these fundamental cell types to disease circuitry in a subtype-specific manner. 
Collectively, this study supports an excitatory/inhibitory phenotype in the ALS condition, which may 
contribute to pathogenesis through the early initiation of aberrant network development, particularly 
as interneurons shape the functional maturation of the cortex.  
 
 
  
 
 
 
 
 
 
Chapter 5 
  
   75  
 
5 GENERAL DISCUSSION 
While once considered a pure motor neuron disorder with limited cortical involvement, the view of 
ALS has evolved substantially in the last decade, and it is now considered a more genetically 
complex, multi-systemic disease with important pathogenic involvement of neuronal and non-
neuronal cells. Indeed, while the classical neuropathological description of ALS focuses on 
degeneration of both upper and lower motor neurons, and undoubtedly the relationship between the 
two is fundamental to the understanding of ALS pathogenesis, it is now recognised that up to 50% of 
ALS patients have cognitive impairment. Frontotemporal dementia, the most common form of 
dementia after Alzheimer’s disease, is considered part of the ALS disease spectrum, as evidenced by 
a combination of clinical neuroimaging, neuropathological and detailed genetic studies.  
In keeping with the increased role of the cortex in the disease, TMS studies have suggested for a 
number of years that cortical hyperexcitability may have a central role in the disease, however, it was 
unclear what that role may be and the underlying basis for such a phenomenon. It was theorised that 
it may be caused by inhibitory deficits, but there was little evidence for this, and the non-cell 
autonomous view of the disease was not yet fully appreciated. Therefore, the potential role of 
interneurons to underlie this phenomenon was unknown, and the view of the disease in the context of 
an inhibitory vulnerability was largely overlooked until advancement in clinical imaging and TMS 
studies was able to further scrutinize the inhibitory system.  
Now there is increasing evidence, including from the studies presented in this thesis, to support a role 
for interneurons in the disease (Figure 5.1).  
5.1 CHARACTERISATION OF CORTICAL INTERNEURON INVOLVEMENT IN THE SOD1G93A MOUSE 
Chapter 2 of this thesis sought to determine if there was a cellular basis for interneuron dysfunction 
in the SOD1G93A mouse model of ALS, in particular if cortical interneurons were affected in key 
disease-associated regions, and how this may manifest relative to disease progression. It was 
hypothesised that specific interneuron populations would be altered in the motor cortex, due to 
evidence of inhibitory deficits in the ALS cortex (Vucic & Kiernan 2006b, Menon et al 2014, 
Shibuya et al 2016) and increased excitability described in both transgenic SOD1G93A models and 
SOD1G93A patients (Vucic et al 2008, Pieri et al 2009). Data revealed a subtype-specific involvement 
of CR- and NPY-expressing interneurons in the motor cortex, which was apparent from symptom-
onset, and supports an inhibitory phase of disease that coincides with the onset of motor neuron 
degeneration in this model (Ozdinler et al 2011, Jara et al 2012, Vinsant et al 2013). Changes in both 
  
 
 
 
 
 
 
Figure 5.1. Timeline of changes in motor neuron pathology, motor neuron 
excitability relative to interneuron alterations in the SOD1G93A mouse.   
The most important and earliest abnormalities reported for the excitatory/inhibitory 
imbalance in the transgenic SOD1G93A mouse model are shown. Weeks before motor 
neurons are lost and overt clinical symptoms appear (P60), widespread pathological 
abnormalities and changes in upper motor neuron excitability (blue) are detected in this 
ALS model. Inhibitory alterations (red) occur throughout the disease time course 
(black), but may constitute an early step in the initiation of the disease. At an early 
developmental stage when motor neurons are reported to be hyperexcitable, cortical 
interneurons are hypoexcitable and have altered morphology. Prior to symptom-onset, 
layer V upper motor neurons begin to degenerate and spines are reduced on their layer 
II/III apical dendrites at a similar time as CR neurites are altered and NPY-interneurons 
are decreased throughout the motor cortex. Hypoglossal motor neurons are also 
reported to be hyperexcitable from P70. By P90 when both upper and lower motor 
neurons have begun to be lost, CR-interneurons begin to be lost from the motor cortex. 
Weeks later (P120) NPY-interneuron cell density is increased in the motor cortex prior 
to end-stage in this mouse model.  
 
  
MOTOR NEURON 
EXCITABILITY
P0 Birth
42% LMNs Hypoexcitable
(Delestree 2014)
HMNs Hyperexcitable
(Fuchs 2013)
HMNs Unchanged from WTs
(Fuchs 2013)
20 Week
NPY increased in 
Motor Cortex Layers I-VI
16 Week 
CR cells decreased in
 Motor Cortex Layers I-IV
8 Week
CR neurites & NPY cells 
decreased in
 Motor Cortex Layers I-IV
Hyperexcitable MNs
(Pieri 2003; Kuo 2004; Zundert 
2008; Martin 2013; Wainger 2014)
P157
Death
P30
Pre-symptomatic 
P60
Symptom onset 
Bipolar & Multipolar Interneurons 
Hypoexcitable &
 increased neurite complexity of 
Multipolar Interneurons
DISEASE TIMECOURSE
Earliest motor behaviour deficits
(Vinsant 2013)
UMNs begin to degenerate
(Ozdinler 2011)
UMN loss begins in motor cortex
(Ozdinler 2011)
LMN loss begins in spinal cord
(Vinsant 2013)
UMN EPSC frequency increased
& decreased dendritic spine density 
 (Fogarty 2015)
P21 
P28 
P10 
12DIV 
SOD1G93A INTERNEURON
FINDINGS
P56 
P34 
P60 
P90 
P70 
P120 
P140 
60% UMN loss in motor cortex
(Ozdinler 2011)P120
MN stress pathways upregulated
(Saxena 2009)
Spine density decreased on UMN 
apical dendrites of layer II/III
 (Jara 2012)
   76  
 
interneuron populations were initially localised to the upper cortical layers of the motor cortex, 
where it was suggested that they either initiate or respond to degeneration of layer V motor neuron 
apical dendrites (Jara et al 2012). CR-interneurons showed a progressive alteration throughout the 
disease, with increased process length initially detected upon symptom onset, and a progressive 
decline in numbers demonstrated later in the disease, providing support for a loss of inhibitory 
function in the disease.  
However, an interesting and unexpected finding of these studies was the contrasting nature of NPY-
interneuron involvement. While initially decreased in the supragranular lamina of the motor cortex, it 
was increased by end-stage throughout the entire motor cortex. It was theorised that the observed 
late-stage increase in NPY may represent attempted compensatory mechanisms aimed at 
counteracting increased excitation, which may be an interesting avenue to explore in future studies 
for assessment of therapeutic potential (Vezzani & Sperk 2004, Kharlamov et al 2007). Indeed, 
extensive literature from the field of epilepsy has suggested that an increase in NPY and decrease of 
CR are both hallmarks of an excitable neuronal network (Kovac & Walker 2013, Toth & Magloczky 
2014). While it remains to be determined if this represents a loss of these inhibitory cell populations, 
or a loss of the proteins that are typically used to characterise to them, it is important to note that 
both the proteins these cells express have important roles in modulating network excitability. More 
specifically, calretinin deficient cells have altered intrinsic neuronal excitability (Gall et al 2003) and 
CR knockout mice have a motor phenotype that worsens dramatically with increasing age, attributed 
to a failure of normal motor adaptation (Schwaller et al 2002). Indeed, in epilepsy studies loss of CR-
expressing populations is also linked to a decline in network function (Toth & Magloczky 2014). In 
comparison, the release of NPY is closely associated with an anti-epileptic neuroprotective role in 
neuronal networks, as increased synthesis of the peptide is described after increased excitability in 
epilepsy models (Vezzani & Sperk 2004, Kharlamov et al 2007). Collectively, these results suggest 
that interneurons have an important role in disease pathophysiology within the motor cortex, and that 
they may have an underappreciated role in the disease, particular related to the onset of motor 
deficits.  
5.2 IDENTIFYING INTERNEURON PATHOLOGY IN THE MOTOR CORTEX OF ALS CASES 
The previous findings from Chapter 2 support the involvement of specific inhibitory populations in 
the SOD1G93A motor cortex; however, it was unknown if this was relevant to the human disease and 
how these populations may be implicated in the context of the ALS motor cortex. As such, Chapter 3 
used a targeted approach to determine if the inhibitory phenotype detected in Chapter 2 translated to 
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the human cortex, and hence validate and build on the insights gained from the SOD1G93A model. It 
was hypothesised that specific interneuron populations affected in the SOD1G93A mouse would also 
be affected in ALS patients and associate with the extent of cortical pathology. For these analyses, 
the CR-, NPY- and CB-interneuron populations were selectively investigated, as they had distinctly 
different patterns of involvement in the SOD1G93A mouse. Although only a small pilot study with a 
limited case numbers, the histopathological analysis provided by Chapter 3 successfully highlights a 
similar pattern of interneuron involvement in the ALS motor cortex to that previously reported in the 
SOD1G93A mouse model (Chapter 2). The findings of this chapter may also highlight a novel 
relationship between interneuron pathology and pyramidal cell loss in the ALS motor cortex that has 
not been previously described.  
While an interesting finding was the divergence of CR-interneuron pathology demonstrated in 50% 
of ALS cases, a perhaps more thought-provoking finding was the positive correlation of CR-cell loss 
with the extent of layer V pyramidal cell loss within the motor cortex. While direct causation of this 
relationship remains to be determined, it may be interesting to further investigate, as a greater extent 
of intracortical inhibitory dysfunction has been linked to more rapid clinical decline and shorter 
disease duration in sporadic ALS patients (Shibuya et al 2016). Conversely, familial SOD1 mutation 
carriers with preserved intracortical inhibitory circuitry have a slower disease progression (Weber et 
al 2000). In the context of the cortical hyperexcitability demonstrated in patients, this may suggest 
that the capacity of cortical interneurons to maintain their inhibitory functions is an important 
homeostatic mechanism to preserve motor neuron function and health in the ALS motor cortex. The 
differential involvement of CR-interneurons may also suggest innate differences in the vulnerability 
of specific interneurons in patients, which may influence the clinical phenotype. While such a link 
was not demonstrated in this study, it cannot be ruled out due to the nature of the small number of 
cases in this pilot study, particularly in the context of the genetic and clinical heterogeneity 
demonstrated in ALS.  
Again we saw an increase in NPY-interneurons in ALS cases, as previously seen at end-stage in the 
SOD1G93A motor cortex in Chapter 2. However, adding to these previous findings a correlation of 
NPY-interneurons was demonstrated between pyramidal neurons and CR-interneurons. In support of 
the neuroprotective role inferred from epilepsy literature discussed in Chapter 2, ALS cases with the 
greatest increase in NPY-populations relative to controls, had the greatest preservation of CR-
interneuron and pyramidal cell density, whereas those cases with NPY-interneuron density most 
similar to controls had the most CR-interneuron and pyramidal cell loss. Again a comparison could 
be drawn between NPY involvement in ALS and that of epilepsy, as the apparent increase of NPY-
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immunoreactive fibers was similar to that previously identified by other studies in the epileptic brain 
(Furtinger et al 2001).  
Collectively, this study supported the findings and interpretations of Chapter 2, advancing our 
understanding of the selective vulnerability of cortical interneurons in the ALS motor cortex and the 
potential cellular basis of functional imaging abnormalities reported in clinical studies. Furthermore, 
given the surmised central role of cortical hyperexcitability in the disease, and the neuroprotective 
role of NPY as endogenous anti-epileptic, it again highlights the need for further investigation of 
these dynamic inhibitory interneuron populations, in regards to their potential to modify or 
compensate pathogenic excitability in the cortical motor network.  
5.3 TESTING THE THEORY OF INTRINSIC INTERNEURON VULNERABILTY IN THE SOD1G93A MOUSE 
While the results of Chapter 2 and 3 provide support to the overarching hypothesis that ALS 
pathogenesis involves cortical interneuron dysfunction, they cannot differentiate if cortical 
interneuron involvement is instigated primary, or secondary to, increased excitability in the disease. 
As described previously inhibitory cell types are highly adaptive such that they may both respond to, 
or initiate, alterations in network excitability in the disease setting. Although increasingly recognised 
as a non-cell autonomous disorder (Boillee et al 2006a, Ilieva et al 2009), which is theorised to 
require multiple hits in order for disease symptoms to manifest (Al-Chalabi et al 2014), there is 
relatively limited knowledge of the innate vulnerability of interneurons in ALS. Key questions that 
may be central to understanding the role of these populations in disease, include determining if the 
motor-specific involvement of populations described in Chapters 2 and 3 are caused by their 
placement in a vulnerable network, secondary to altered states of excitability, or whether there is an 
innate susceptibility of these cells that may insidiously prime networks to fail later in life. Therefore, 
Chapter 4 of this thesis aimed to determine the effect of the SOD1G93A mutation on interneuron 
development, with the hypothesis that the SOD1 mutation would affect the intrinsic function of 
interneurons and their normal development in vitro, adding to the timeline of findings from this 
thesis (Figure 5.1). This was theorised, as there is considerable evidence of increased 
hyperexcitability during early neonatal and embryonic stages in ALS models (Pieri et al 2003, Kuo et 
al 2004), and intrinsic alteration of motor neuron and excitatory cortical neuron populations is 
demonstrated (Pieri et al 2009, Quinlan et al 2011), while it is also appreciated that aspects of 
interneuron development are an activity-dependent process (Cancedda et al 2007, De Marco Garcia 
et al 2011, Kepecs & Fishell 2014).  
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Data from Chapter 4 suggests for the first time that cortical interneuron populations are innately 
susceptible to the presence of an ALS mutation, with intrinsic firing parameters and intrinsic 
excitability altered in both multipolar and bipolar cortical interneurons. While the contrasting 
alteration of key firing parameters suggests differential responses to the disease, potentially due to 
innate differences of cells and embryonic origins, these findings critically indicate that distinct 
interneurons may have a role in instigating an excitatory/inhibitory balance from early stages of 
development. The hypoexcitable nature of these interneurons could contribute to reduced network 
inhibition and increased network hyperexcitability. Therefore, inferring a potential primary role of 
cortical interneuron dysfunction in the disease, which must remain compensated for throughout the 
majority of disease until compensatory mechanisms fail, inhibitory function is lost, potentially 
through loss of CR-interneurons, and the disease manifests as cortical hyperexcitability. It is then 
proposed that this later phase of network hyperexcitability, underscored by inhibitory decline, 
transitions to hypoexcitability as cells undergo excitotoxic glutamatergic overload, and are lost from 
the functional network, resulting in the phenotypic motor neuron decline (Figure 5.2). 
Importantly, potential compensation exerted by interneuron in the disease may have merit as 
differences in the ability of interneuron subtypes to respond through activity-dependent processes is 
demonstrated through the differential morphological response of bipolar interneurons compared with 
multipolar interneurons. Interestingly, the demonstration of increased neurite path length in 
multipolar interneurons in this chapter was comparable to the increased length of processes reported 
at symptom onset in CR-interneurons in Chapter 2. The alteration of neurite path length is thought to 
be an activity-dependent mechanism (De Marco Garcia et al 2011), which may suggest that altered 
morphology reflects an adaptive response to increased excitability in the cortex and cortical cultures 
with the SOD1G93A mutation. However, this morphological response of interneurons was not 
universally demonstrated, with bipolar interneurons largely unchanged compared to controls in this 
respect. This may indicate that while select inhibitory populations do have an ability to compensate 
for the pathogenic environment initiated in the disease, others do not.  
5.4 FUTURE DIRECTIONS AND LIMITATIONS 
This thesis focused on characterising the extent and timing of cortical interneurons in the motor 
cortex of the most widely used model of ALS the SOD1G93A mouse, the validity of interneuron 
involvement in the ALS motor cortex and the potential for cortical interneurons to be intrinsically 
susceptible to a known ALS mutation during development. The characterisation of cortical 
interneurons in Chapter 2 and 3 primarily utilised immunohistochemical assessment to investigate 
  
 
 
 
 
Figure 5.2. Potential mechanisms of inhibitory system contribution to motor 
neuron failure in amyotrophic lateral sclerosis.  
Based on the developmental occurrence of inhibitory and excitatory motor neuron 
deficits, and the subsequent timeline of structural alterations, a model is proposed in 
which this early inhibitory/excitatory imbalance may initiate a diverse cascade of 
secondary compensatory mechanisms, including CR-interneuron alterations, which will 
influence the development and functioning of neuronal circuits and prime motor 
networks to fail later in life. a, In normal physiological conditions, heterogeneous 
populations of interneurons innervate different domains of upper motor neurons, and 
provide regulatory inhibition of excitability. b-g, In a pathogenic disease setting, 
interneurons may be involved in multiple facets of excitability misregulation. b-c, 
Primary interneuronal dysfunction originating during early development (b) may result 
in upper motor neurons becoming hyperexcitable through loss of inhibition (c). d-e, 
Secondary interneuronal dysfunction may occur when upper motor neurons are initially 
hyperexcitable (d), leading to inappropriate interneuron development and function (e). 
Therefore, the failure of either interneurons or motor neurons to regulate excitability 
can lead to the motor system being primed to fail. f, The inhibitory system has an 
innate capacity for plasticity. Therefore, a degree of compensation and restoration of 
normal excitation by the inhibitory system may exist in the preclinical phase of disease. 
g, Onset of disease may become apparent when compensatory mechanisms become 
saturated or fail, due to accumulation of age-related pathogenic mechanisms, including 
inhibitory failure, leading to the failure of excitability regulation in the motor circuit 
and motor neuron degeneration.  
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potential involvement in the disease. While, the immunohistochemical assessment of human post-
mortem tissue is traditionally utilised to great affect in many neuropathological case studies (Nihei et 
al 1993, Neumann et al 2006, Brettschneider et al 2013, Kim et al 2014a, Fatima et al 2015), 
alternative assessment strategies might include the quantification of mRNA abundance via in situ 
hybridization protocols to support changes in protein levels detected by immunohistochemistry (Liu 
et al 2010). Another method that can surpass such limitations is the use of transgenic mice that have 
Cre driver lines specific for distinct interneuron subtypes in the cortex (Taniguchi et al 2011). This 
may prove a more specific approach for investigating both CR- and NPY-interneuron populations, 
for example by crossing the B6(Cg)-Calb2tm1(cre)Zjh/J CR-transgenic mouse with the SOD1G93A 
mouse, genetic GFP labelling can be used to conclusively assess the role of this cell type in the 
motor cortex circuit and resolve the question of whether the protein or cell is altered.  
Such an approach may also prove useful for investigating the innately differential responses of 
bipolar and multipolar interneurons to the SOD1G93A mutation in Chapter 4. If the innate responses 
of these two populations are determined by their different embryonic origins, caudal/lateral or medial 
ganglionic eminence, this may be investigated by following the development of these cells with 
genetic fete mapping studies in ALS mouse models (Miyoshi et al 2007, Miyoshi et al 2010). 
However, more directly in the context of inhibitory dysfunction, it would be interesting to conduct 
further electrophysiological examination to assess if inhibitory post-synaptic potentials generated by 
these cells are altered. Additionally, it would be interesting to explore if synaptic scaling occurs in 
these cells, as this represents a homeostatic regulatory mechanism which allows neurons to altering 
synaptic strength to respond to prolonged changes in the cells intrinsic electrical activity (Turrigiano 
2012). Without homeostatic synaptic scaling, neuronal networks can become unstable. Interestingly 
this mechanism is thought to activity-dependent process modified by glia (Stellwagen & Malenka 
2006), therefore it may be of interest to explore this firstly due to the altered intrinsic excitability 
demonstrated in Chapter 4, but also due to the suspected involvement of microglia in the onset of the 
disease (Boillee et al 2006b, Casas et al 2016).  
Another consideration for future studies may be the investigation of the expression of GABA 
receptors profiles on interneuron populations, as the formation and function of the inhibitory circuit 
rely on excitatory and inhibitory synapse formation, including the GABA receptor profile of 
interneurons. As previously described in Chapter 1 and 3, there is evidence of reduced GABAA 
receptor expression and binding in ALS patients (Lloyd et al 2000, Petri et al 2003). Given the 
differential involvement of interneuron populations described in Chapters 2, 3 and 4, it would be 
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interesting to see if the receptor composition is differentially affected in these different interneuron 
subtypes at varied stages of disease.  
A receptor-based approach may also allow for further insight into the role of NPY in the disease. As 
a potential neuroprotective compound it will be interesting to assess brain levels of NPY receptors in 
ALS patients, as this may predict the efficacy of a therapeutic strategy centred around harnessing it’s 
endogenous therapeutic potential. The use of specific radioligands to determine the distribution and 
kinetics of NPY receptor binding has been previously demonstrated in both in vitro and in vivo 
receptor-autoradiography studies in Alzheimer’s disease (Martel et al 1990) and epilepsy (Furtinger 
et al 2001). This may be an interesting avenue for future research due to the increase in NPY 
demonstrated throughout the motor cortex in Chapter 2 and 3. Investigation in other mouse models 
would also build a more holistic picture of the potential role of NPY in the disease and should be 
considered for future studies (Leitner et al 2009). In particular, it would be of interest to determine if 
NPY administration may preserve motor circuitry, further investigating the correlation of NPY, with 
CR and pyramidal cell pathology identified in ALS cases, but not explored in the SOD1G93A mouse 
model. Nonetheless, in line with the broader pathogenesis of the disease, it is notable that more 
recent studies suggest that the neuroprotective properties of NPY may also extend to the suppression 
of excitotoxicity and regulation of calcium homeostasis (Duarte-Neves et al 2016). Therefore, the 
role of NPY-interneurons and the NPY peptide warrant further investigation.  
Collectively this thesis has highlighted that interneuron involvement in ALS may be considerably 
more complex than previously appreciated, with multiple inhibitory compensatory mechanisms and 
innate susceptibilities most likely occurring over the disease course. Further characterisation of 
cortical interneuron vulnerability and the impact these cells have on the function of the cortical 
motor circuit needs to be made a priority, as it has the potential to lead to important therapeutic 
strategies for the treatment and prevention of ALS.  
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5.5 CONCLUSIONS 
Altered excitability and the processes leading to loss of motor neuron function in ALS are complex 
and multifactorial. This thesis provides significant evidence to suggest that cortical interneuron 
dysfunction has an important and potentially evolving role in this process. It also supports an 
increasing cortical and non-cell autonomous nature of the disease, providing a novel perspective on 
the cellular basis for inhibitory dysfunction in the motor cortex of the SOD1G93A mouse model and in 
ALS patients. In summary, the findings of this thesis indicate that cortical interneuron populations 
may have a complex and evolving role in the disease, which may be initiated early during 
development and culminate in the failure of specific interneuron populations to compensate for 
dysfunction later in life. However, there is potential for inhibitory compensatory mechanisms, with 
future evaluation of inhibitory-based therapeutic strategies recommended as these compounds may 
be of great therapeutic benefit for the amelioration and normalisation of excitability in ALS.  
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